CA2557301A1 - Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease - Google Patents

Abstract

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Description

CYCLOBUTENEDIONE GROUPS-CONTAINING COMPOUNDS AS INHIBITORS OF HEPATITIS C
VIRUS

Field of the Invention The present invention relates to novel hepatitis C virus ("HCV") protease inhibitors, pharmaceutical compositions containing one or more such inhibitors, methods of preparing such inhibitors and methods of using such inhibitors to treat hepatitis C and related disorders. This invention additionally discloses novel compounds as inhibitors of the HCV NS3/NS4a serine protease. This application claims priority from U.S, provisional patent application Serial Number 60/548,823 filed February 27, 2004.
Background of the Invention Hepatitis C virus (HCV) is a (+)-sense single-stranded RNA virus that has been implicated as the major causative agent in non-A, non-B hepatitis (NANBH), , particularly in blood-associated NANBH (BB-NANBH) (see, International Patent Application Publication No. WO 89/04669 and European Patenfi Application Publication No. EP 381 216). NANBH is to be distinguished from other types of viral-induced liver disease, such as hepatitis A virus (HAV), hepatitis B virus (HBV), delta hepatitis virus (HDV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), as well as from other forms of liver disease such as alcoholism and primary biliar cirrhosis.
Recently, an HCV protease necessary for polypeptide processing and viral replication has been identified, cloned and expressed. (See, e.a., U.S. Patent No.
5,712,145). This approximately 3000 amino acid polyprotein contains, from the amino terminus to the carboxy terminus, a nucleocapsid protein (C), envelope proteins (E1 and E2) and several non-structural proteins (NS1, 2, 3, 4a, 5a and 5b). NS3 is an approximately 68 kda protein, encoded by approximately 1893 nucleotides of the HCV
genome, and has two distinct domains: (a) a serine protease domain consisting of approximately 200 of the N-terminal amino acids; and (b) an RNA-dependent ATPase domain at the C-terminus of the protein. The NS3 protease is considered a member of the chymotrypsin family because of similarities in protein sequence, overall three-dimensional structure and mechanism of catalysis. Other chymotrypsin-like enzymes are elastase, factor Xa, thrombin, trypsin, plasmin, urokinase, tPA and PSA.
The HCV
NS3 serine protease is responsible for proteolysis of the polypeptide (polyprotein) at the NS3/NS4a, NS4a/NS4b, NS4b/NSSa and NSSa/NSSb junctions and is thus responsible for generating four viral proteins during viral replication. This has made the HCV NS3 serine protease an attractive target for antiviral chemotherapy.
The inventive compounds can inhibit such protease. They also can modulate the processing of hepatitis C virus (HCV) polypeptide.
It has been determined that the NS4a protein, an approximately 6 kda polypeptide, is a co-factor for the serine protease activity of NS3.
Autocleavage of the NS3/NS4a junction by the NS3/NS4a serine protease occurs intramolecularly (i-e., cis) while the other cleavage sites are processed intermolecularly (i.e., trans).
Analysis of the natural cleavage sites for HCV protease revealed the presence of cysteine at P1 and serine at P1' and that these residues are strictly conserved in the NS4a/NS4b, NS4b/NSSa and NSSa/NSSb junctions. The NS3/NS4a junction 1~5 contains a threonine at P1 and a serine at P1'. The Cys-~Thr substitution at NS3/NS4a is postulated to account for the requirement of cis rather.than trans processing at this junction. See, e.g_, Pizzi et al. (1994) Proc. Natl: Acad.
Sci (USA) ' 91:888-892, Failla et al. (1996) Folding & Design 1:35-42. The NS3/NS4a cleavage site is also more tolerant of mutagenesis than the other sites. See, e.g"
Kollykhalov et al. (1994) J. Virol. 68:7525-7533. It has also been found that acidic residues in the region upstream of the cleavage site are required for efficient cleavage. See, e.g., Komoda et al. (1994) J. Virol. 6:7351-7357.
Inhibitors of HCV protease that have been reported include antioxidants (see, International Patent Application Publication No. WO 98/14181 ), certain peptides and peptide analogs (see, International Patent Application Publication No. WO
98/17679, Landro et al. (1997) Biochem. 36:9340-9348, Ingallinella et al. (1998) Biochem.
37:8906-8914, Llinas-Brunet et al. (1998) Bioorq. Med. Chem. Lett. 8:1713-1718), inhibitors based on the 70-amino acid polypeptide eglin c (Martin et al.
(1998) Biochem. 37:11459-11468, inhibitors affinity selected from human pancreatic secretory trypsin inhibitor (hPSTI-C3) and minibody repertoires (MBip) (Dimasi et al.
(1997) J. Virol. 71:7461-7469), cVNE2 (a "camelized" variable domain antibody fragment) (Martin et a1.(1997) Protein Ena. 10:607-614), and a1-antichymotrypsin (ACT) (Elzouki et al. (1997) J. Hepat. 27:42-28). A ribozyme designed to selectively destroy hepatitis C virus RNA has recently been disclosed (see, BioINorld Today 9 217 : 4 (November 10, 1998)).
Reference is also made to the PCT Publications, No. WO 98/17679, published April 30, 1998 (Vertex Pharmaceuticals Incorporated); WO 98/22496, published May 28, 1998 (F. Hoffmann-La Roche AG); and WO 99/07734, published February 18, 1999 (Boehringer Ingelheim Canada Ltd.).
HCV has been implicated in cirrhosis of the liver and in induction of hepatocellular carcinoma. The prognosis for patients suffering from HCV
infection is currently poor. HCV infection is more difficult to treat than other forms of hepatitis due to the lack of immunity or remission associated with HCV infection. Current data indicates a less than 50% survival rate at four years post cirrhosis diagnosis. Patients diagnosed with localized resectable hepatocellular carcinoma have a five-year survival rate of 10-30%, whereas those with localized unresectable hepatocellular carcinoma have a five-year survival rate of less than 1 %.
Reference is made to WO 00/59929 (US 6,608,027,.Assignee: Boehringer ;Ingelheim (Canada) Ltd.; Published October 12, 2000) which discloses peptide . .
'.derivatives of the formula:
Rz~ ~ \ Rzz O

,,, R4~ O
Reference is made to A. Marchetti et al, Synlett, S1, 1000-1002 (1999) describing the synthesis of bicylic analogs of an inhibitor of HCV NS3 protease. A
compound disclosed therein has the formula:

H O
AcHN N v 'OH
1 sH
COOH
Reference is also made to W. Han et al, 8ioorganic & Medicinal Chem. Lett, (2000) 10, 711-713, which describes the preparation of certain a-ketoamides, a-ketoesters and a-diketones containing allyl and ethyl functionalities.
Reference is also made to WO 00/09558 (Assignee: Boehringer Ingelheim Limited; Published February 24, 2000) which discloses peptide derivatives of the formula:

Z~
O
O R~
H

\N
O RS O
where the various elements are defined therein. An illustrative compound of that series is:

O

Reference is also made to WO 00/09543 (Assignee: Boehringer Ingelheim Limited; Published February 24, 2000) which discloses peptide derivatives of the formula:
A~
O
R5 R4 ,,, O

\A3 H
O H
O

5 where the various elements are defined therein. An illustrative compound of that series is:

CHZ
O
Reference is also made to U.S. 6,608,027 (Boehringer Ingelheim, Canada) which discloses NS3 protease inhibitors of the type:

R2~ ~ W R2z i O
~ A
R~
R~~ O
R4 ,,D...
wherein the various moieties are defined therein.
Current therapies for hepatitis C include interferon-a (INFa) and combination therapy with ribavirin and interferon. See, e.a., Beremguer et al. (1998) Proc. Assoc.
Am. Physicians 110 2 :98-112. These therapies suffer from a low sustained response rate and frequent side effects. See, e.a., Hoofnagle et al. (1997) N. Enal. J.
Med.
336:347. Currently, no vaccine is available for HCV infection.
Reference is further made to WO 01/74768 (Assignee: Vertex Pharmaceuticals Inc) published October 11, 2001, which discloses certain compounds of the following general formula (R is defined therein) as NS3-serine protease inhibitors of Hepatitis C
virus:
N H'C CH3 O
N~ O
N II H
O H3C~CH3 A specific compound disclosed in the afore-mentioned WO 01/74768 has the following formula:
N H3C CH, CH3 O
N~ O
N~ ~ \H O O O
O ~ N CHI
H3C CH3 ~ N
'H
O
O
\N
O

PCT Publications WO 01/77113; WO 01/081325; WO 02/08198; WO 02/08256;
WO 02/08187; WO 02/08244; WO 02/48172; WO 02/08251; and pending U.S. patent application, Serial No. 10/052,386, filed January 18, 2002, disclose various types of peptides and/or other compounds as NS-3 serine protease inhibitors of hepatitis C
virus. The disclosures of those applications are incorporated herein by reference thereto.
There is a need for new treatments and therapies for HCV infection. There is a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.
There is a need for methods of treatment or prevention or amelioration of one or more symptoms of hepatitis C.
There is a need for methods for modulating the activity of serine proteases, particularly the HCV NS3/NS4a serine protease, using the compounds provided herein.
There is a need for methods of modulating the processing of the HCV
polypeptide using the compounds provided herein.
Summary of the Invention In its many embodiments, the present invention provides a novel class of inhibitors of the HCV protease, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment or prevention of HCV or amelioration of one or more of the symptoms of hepatitis C using one or more such compounds or one or more such formulations. Also provided are methods of modulating the interaction of an HCV polypeptide with HCV protease. Among the compounds provided herein, compounds that inhibit HCV NS3/NS4a serine protease activity are preferred. The present invention discloses compounds, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers or racemates of said compounds, or a pharmaceutically acceptable salt, solvate or ester of said compounds, said compounds having the general structure shown in structural Formula 1:

M A
~L ~ O
N R~
N

~O

Formula I
wherein:
R~ is H, OR8, NR9R~°, or CHR9R~°, wherein R8, R9 and R~° can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, heterocyclyl-, arylalkyl-, and heteroarylalkyl;
A and M can be the same or different, each being independently selected from R, OR, NHR, NRR', SR, S02R, and halo; or A and M are connected to each other ,10 such that the moiety:
M A
L-E
shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl;
E is C(H) or C(R);
L is C(H), C(R), CH2C(R), or C(R)CH2;
R, R', R2, and R3 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cycloalkyl)alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-; or alternately R and R' in NRR' are connected to each other such that NRR' forms a four to eight-membered heterocyclyl; and Y is selected from the following moieties:

Y3o Y3o Y3o R~9~G~.~ R~s ~~~ R~9 G
R~~ Rya or 0_4 0_3 wherein Y3° is selected from T~. ~~ 5 , (p1 l-1 N N~ ~ ~~ s i a ~ 0-2\ 7S
TZ Ts T~ Ts O O
s T~ N ~~

where a is a number 0-1;
X is selected from O, NR~5, NC(O)R~6, Sy S(O) and S(02);
G is NH or O; and R'5, R~6, R'7, R~8, R'9, T~, T2, and T3 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or alternately, R~' and R~$ are connected to each other to form a three to eight-membered cycloalkyl or heterocyclyl;
wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkyl, aryl, heteroaryl, alkylsulfonamido, arylsulfonamido, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano, and nitro.
The above-noted statement "A and M are connected to each other such that the moiety:

M A
L-E
shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl" can be illustrated in a non-limiting matter as follows.
5 Thus, for example, in the case where A and M are connected such that the moiety:
M\L E/A
shown above in Formula I forms a six -membered cycloalkyl (cyclohexyl), Formula I
can be depicted as:
L E
N R~
Y N O R O
O R
One with ordinary skill in the art will appreciate that similar depictions for Formula I
can be arrived at when A and M shown above in the moiety:
M A
L-E
(M-L-E-A taken together) are connected to form a three, four, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl.
In the above-noted definitions of R, R', R2, and R3 preferred alkyl is made of one to ten carbon atoms, preferred alkenyl or alkynyl is made of two to ten carbon atoms, preferred cycloalkyl is made of three to eight carbon atoms, and preferred heteroalkyl, heteroaryl or heterocycloalkyl (heterocyclyl) has one to six oxygen, nitrogen, sulfur, or phosphorus atoms.
The compounds represented by Formula I, by themselves or in combination with one or more other suitable agents disclosed herein, can be useful for treating diseases such as, for example, HCV, HIV, AIDS (Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C
virus (HCV) protease, preventing HCV, or ameliorating one or more symptoms of hepatitis C. Such modulation, treatment, prevention or amelioration can be done with the inventive compounds as well as with pharmaceutical compositions or formulations comprising such compounds. Without being limited to theory, it is believed that the HCV protease may be the NS3 or NS4a protease. The inventive compounds can inhibit such protease. They can also modulate the processing of hepatitis C
virus (HCV) polypeptide.
Detailed Description In an embodiment, the present invention discloses compounds which are represented by structural Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are as defined above.
In another embodiment, R' is NR9R1°, and R9 is H, R1° is H, or R~4 wherein R'4 is H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl, alkenyl, alkynyl or heteroaryl-alkyl.
In another embodiment, R14 is selected from the group consisting of:
~Me 1_4 1_4 F
~ ~ ~'(~'~ , 1_3 1_3 1_3 \ F
, , 1_4 , 1_4 , OH OH

-OH, ~-OMe, ~~OMe , ~~OH , Me Me Me ~~OH '~ / I ' '~ N ' '~. / I , Me ~N \ I ~N
I
\ I , , //~\~N
N
Me I / ' ~ ~ N> , ~ ' \ and ~., \ I
' 1-3 ~ 1-3 ~ 1-3 , In another embodiment, R2 is selected from the group consisting of the following moieties:
i ' CH3 ' > > ~ ~ ~ , ~ , F F ,""", F ~ F/ \F F
F3cJ
CF3 F CHa ' F
F ~ I , , F F

~z. ~ F F
F
F ' F ' NC ' / ' , F FsC
(~ ' O ' S , , , <" 0-3 F OH
S(O)0-2 ' CH ' ~ ' CH3 , S~0)o-2 CHs CH3 , .~" '~ F '~.
F
, , , F F O n=0-3 n=0-3 n = 0-3 F F F and , S F .
In a further embodiment, R3 is selected from the group consisting of:
,""", ~
CH3 _O
~ ~ CH3\I
CH3 'CH3 , CH3~CHg ' CH3 ~ ~SCH
CH3 CH3 ' ~ ' H3C 3 ' """" CH3\I C02Et 0_4 , ~ / ~ , , , HsC
OJ F F

, , , ' ' ~ F

F F
F
,""", ,""", .""", H3C~ ~ ~_3 , , ' ' J ' CF3 S COOH
i~
O
,""", CH3 O"CH3 ' ~ CH ~CH , CH3 COR3~ COR3~ 3 CH 3 N
~~~"' M a Me " ~ c> >
O
Nn~ N~N
I N NV
~Me R3~ NHR32 CH3\j ~
F C ' ~ ' SBn , HO"CH3 COON H3C , """
~COOH , ' , CH3' CHCH3 0 So O
3 ,N...!
Me , , Me Me ~ 0-3 F3C CF3 OH

CI CI Me Me F , F
' . and H3C~CH3 1..130 CH3 wherein R31 is OH or O-alkyl; and R32 is H, C(O)CH3, C(O)OtBu or C(O)N(H)tBu.
5 In an additional embodiment, R3 is selected from the group consisting of the following moieties:
CH3 'CH3 ~ CH3~CH3 CH3~CH3 CH3 CH3 , R31 ' CH3 """", """,~ ,""", ,""",.
, ~, , , , , J ~ ~ ~CH3 ~ _ J
CH3' CHCH3 ~ ' Me Me ' ~ s ' O S~ ' , CI CI

CH3 CF3 ~
Me~CF3 and °-3 , Me F F F F
In an yet another embodiment, G is NH.
In a further embodiment, Y is selected from the following moieties:
R1g R19 [via " H
H
R1g N Y3o N\~ Y3° N\~ Y3o N~~ Yso Nw Yso R1g R1s R

H
R19 N Yso Ny Yso Ny Yso Ny'' ~ Me -J 0_3 ~ 0-3 Y3° N\ Yso N.~~ . Yso N~~-R1s R1g R19 H R1g H R1g H H
Y3° N \ Y3o N y Y3° N y' Yso N ~~ so w Y N

F F

H R1g H H
Y3° N \~ Y3° N ~~ so N ~ Yso N y Yso N ~~
Y
and wherein Y32 is selected from the group consisting of:
H , O , o , O~ ~O and O
Y3° is selected from T~. -1 N N ~~ O ~~ l s T2 T3 0-2 ~ ~S
T1 Ts i!~ S
T~

where a is a number 0-1;
and R19 is selected from H, alkyl, phenyl or benzyl.
In a still additional embodiment, T1 and T2 can be the same or different, each being independently selected from the group consisting of:
~ '.~. ~ N
CFg~~s CF3~"~ ~ ~~ X15 i / ~ ~ ~ sr N ~'' N
O . 'vw.
N / N /
O TTN
S ~ ~ ,sr' 2 1 S
N N ~(N ~ T T N~~ T T N
~..2'~.1N~~ '~2T1N~~~ 2 1 N ~ 2 1 O
S ~ S ,~ H
N
0 ~ H ~' ~ H N
and X1 or the moiety:

T~~N ~ taken together represents N~~ GN~~ N~~ ~N~~
C G
~N~~ ~N~~
or Ys2'NJ
and T3 is selected from:
H CH3~ ~~ ~F~
CF3~~. CF ~~ ~~~ R~s i ~ R15 ~ or 1-4 In a still further embodiment, the moiety:
M A
L E
N
O
~O
is selected from the following structures:
Me Me Me H O Me O ~Me ~ Me H , ~ H ,~ H , N ~ N
N
O
CI~CI 'F~F Br O ,,~ Br I o I
N ~N N
I I
O O O

Me ~Me O
O ,O
~N
O
Me R O I/Me H ~H
H O
O H 0 H , 0 H , ,~ N ,~ N ,~ N ,~ N
p O O O
~0-4 O ' O
~N~ ~N~ w O N II
O O ~O w O
~O

M ~Me O
O
~N~ , , , N ~ N
O
Me _ I/Me ~O
O ' 0 ' O
N ~N~ ' N II
O O
O
S
OS OS S O
I
, ~N ~N , ~N~
p O
Me Me ,Me O , O , O , ~N ~N~~ ~N~
p O O
Me Me Me Me O Me Me I ~/' ~N ' ~N~ ~N I
O O p O
~O ~ \ O
O O , >
~N~ , ~N ~N
O
O H CI
\ OS O \ Nw ~ \ O
NH ~ CI~

' ~ and ~ ~
N N N' Y
I I IO
O O
In a further embodiment, the moiety:

M
L
~O
is selected from the following structures:
Me Me I/ Me ~Me H O
°~'' O H O ,O
OI I I
' ~aN ~N
N
O O
CI Br ,,,~cl F~F
I O O ,~Br ~N
N
~ N
O
O
Me O~Me O
O
I ~ ~N I
is N O
O
Me~ /Me Me Me O ~ O
~N~ I = , O
PhOS. O ph~NH
NH
p O ' O
~N~ ~~ ~N~
O O IIO
a I N ~ ~/' ~N~ ~ \ ~ ' N II and N II
O ~O ~O O ~w O

In a further embodiment, the moiety:
M A
L E
N
O
O
is selected from the following structures:
CI~CI F F -u N~ ' N~ ' N
~O I I d 'O O d 'O O
Br~Br N , ~ ~
w O N II N II
~O ~~O p and ~~O O
In a still additional embodiment, R1 is NHR14, where R14 is selected from the group consisting of:
~~ Me , F
i ' ~'~.~ , ~ , 1_3 1_3 1_3 , wF
, 1_4 , 1_4 , -OH, ~-OMe, ~~OMe , ~~OH , Me Me Me '~~OH '~ / '~ N '~,L i Me ' ~N I ' \ I ' ~N
'~' \ I , '~' ~N I . '~'' i I ,,~.,,, n-1-3 SMe ,~~OH
\ N - ~'' S Me ' ~ S> > / ~ and 1-3 ~ 1_3N ~ 1_3 \ ~ .
R2 is selected from the group consisting of the following moieties:
H ~ CH3 ~ CHI > , ~ , ~ ~ y > > ~ , , CH3 ~ ' I 'F F , F ~ F~F F
> > F3CJ , CH2F CFs F CHa CHF2 F '"'""
F , ~ ,, n=0-3 ( F F ' JIIW
F F
F
NC ' F ' / , F ' F ' F3C
' O ~ S , 0-3 ' ' F OH
J~MI
~S(O)o-2 CH ' O , CH3 , S(O)o-2 CH3 CH3 , F '~.
F
F F O " n = 0-3 n = 0-3 F F F and ' ' ' g " F
R3 is selected from the group consisting of the following moieties:
CH3 'CH3 CH3' I 'CH3 CH3~CH3 CH3 CH3 ~ R31 ' CH ' 0-4 JVWV JV~N JWV JWIn J1M/1 -, O F F ~ COR31 OJ -CHs -CHs ~ 03 . S
CHs' CH3 Hs , OH ' Me Me , CFs COsH C02H
CI CI
CF3 ~
Me' I 'CF3 and °_3 , Me F F F F .
, Y3° is selected from the group consisting of:
T3 Ts T3 i i 0_1 i N ~,, , N ~~,., , N ~,., O O O~O O~~O

N~.' ' ~ N~' and 5 O~ ~O O~ ~O O O
and also wherein Y3° is selected from the group consisting of:
°_1 T3 °_1 Ts °_1 Ts Y1I W N \.ss , ~ N W.rr's , S ~ N W.~'s \S ~

0_1 Ts o_1 Ts N~ ~ N~~ , ~ N
S , O~O \ O ~ , O O

0_1 0-1 T3 0-1 T3 N~ N y.'~' , N ~ _ N ~.F's I N~ N ~.'S
~N
O O N O O N O O
01 3 Ts °-1 Ts 0-1 i N ~ N
N~.~'~ and N , O O N O O O O

and also wherein Y3° is selected from the group consisting of:
T3 T3 ~ T3 T3 T3 T3 N N~~., ~ I N N ~,, ~N N~~, ~l, O O O O O O

T3 O I IT3 N ~ T3 N N ~N _ N~~ , ~N N~.
0-2 ~~ O O O O
O O
,O, T3 CO) 0-2 T3 ~O)o-2 T3 S _ N~~ and ~(.~-S N~.~''s O O O O
O O
Y32 is selected from the group consisting of:
~O~'~ ~°~'~
H , - I O , O , °,, ~O and and Y~2 is selected from the group consisting of H, CO2H, C02Me, OMe, F, CI, Br, NH2, N(H)S(02)CH3, N(H)C(O)CH3, ~N02, NMe2, S(O2)NH2, CF3, Me, OH, OCF3, and C(O)NH2 ;
Y33 is selected from the group consisting of:
Hi~' ' Me~~ °r ~' and T3 is selected from:
H CH3~~ ~~ CF3~~. CF ~~s pr and the moiety:
M A
L-E
~N
O
O
IS:

Me / \ FsC
,~ Me O ,,.- ~~ , ~ , O I , ~ O ~N~
~N , ~N~ ~N~ O
O O
F
F Br~Br CI~CI
' N~ , O 1~ O
, ~w O ~N , ~ , ~N
w O ' O ~~. O
~O O ~O O
Me O~ CI
~Me ~ O
O
O , , ~~ N
N 1~ O 1 o or ~N ~ ~ O
O O ~O ~o ~O
Yet another embodim~en't of the invention discloses compounds shown in Table 1 and later in Table 2. Also shown in the Table 2 are the biological activities of several inventive compounds (as Ki* values).

U

NHZ
O
O O ~ O
O
~NH
-N N I'O
%~ H
~N NH
/~ O ~ 00 O
~N NH O O O\/NH
O ~O'I O N ~NH
O O O"NH
N ~N'H
O
/'~ H
~N NH
O ~ O ~O'I O
NH O O O\/NH
O O O N 'N~H
O O O~NH
N NH

/~ o '~N NHZ
~~O O O
O O p~ 1NH
~N~N NH
O ~ ~ O
NH ~~ NH
O O ~ O\ 'O ~O O O
r ~H
O O p~NH ( ( I i N o NH
I
O NHZ '~N N
O TOI O
O O ~ O O
\N N N~NH O O O O~NH
p IOI N NH
w :. 0 0 '~N NHz N NHZ
~~O rOI O
O
O O O "NH
N ~N'H
H
O
NH ~ NH
O O O
-N
O
O O
N~

%~ 0 ~N NHS
~~O O O
O O O_ -NH O
N ~NH
H N
O
H
N NH
O
O
NH

o /\~/ o N NH2 '~N NH
O ~~O ~O[ O
O O O~O
N \N OyNH II
H ~ H
O ~ O
NH
N N\
~~O O O '~O
O O O"NH
N ~N'H
O_, ,.O O O
~N~N
H

%~ 0 '~N NH
~~O ~'OI O
O O O"NH
N ~N'H
H
O O
N NHZ N NH
O

O O p"NH
,\~~N ~N'H

N

O O O O
~~~N~ ~N~N N
I ~ H
O ~ ~ O
'N' N NH 'N' N NH
O O O ~~O O O
O O O_ -NH O O O\'NH
N ~NH 'N~H
H~ I
NHz NH N NHz O
O O
N
O
NH NH

O O O"NH
N ~N'H
O
NH
~~O O O
O O O"NH
~,~N ~N'H

\I Nf: ~ O
~O O O
O O p~NH
~N~N NH
O
NHS
O O
O
NHZ
O/-10 ~ p O
O
_ I I ~NH
I IO
O~O
I
\/

As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain.
More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkyl" means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -N(alkyl)2, carboxy and -C(~)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkenyl" means that the alkenyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. The term "substituted alkynyl" means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be,optionaliy substituted with one or more "ring system substituents" which may, be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl"
can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or this before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like.
The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.
"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbor~..atoms~ preferably about 5 to about 10 w carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionsllysubstituted with one or more'"ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like.
"Halogen" or "halo" means fluorine, chlorine, bromine, or iodine.
Preferred are fluorine, chlorine and bromine.
"Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, 4~
heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), Y~Y2N-, Y~Y2N-alkyl-, Y~Y~NC(O)-, Y~Y2NS02- and -S02NY~Y2, wherein Y~ and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. "Ring system substituent" may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH3)2- and the like which form moieties such as, for example:
~--o o , Co o and "Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one c~r~mor~ of the atoms in the ring -system is an element other than carbon, for ex~rropie nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen andlor sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any-NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like;
such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or difFerent, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:

N
H
there is no -OH attached directly to carbons marked 2 and 5.
5 It should also be noted that tautomeric forms such as, for example, the moieties:
N O
H and N OH
are considered equivalent in certain embodiments of this invention.
"Alkynylalkyl" means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent..rrr~oiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl gr~ups include . propargylmethyl. , "Heteroaralkyl" means a heteroaryl-alkyl- group.in vnhich the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
"Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio: The bond to the paeent moiety is through the sulfur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.

"Alkylsulfonyl" means an alkyl-S(02)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
"Arylsulfonyl" means an aryl-S(02)- group. The bond to the parent moiety is through the sulfonyl.
The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The term "one or more" or "at least one", when indicating the number of substituents, compounds, combination agents and the like, refers to at least ~
:. ~. .
. one, and up to the maximum number of chemically and physically permissible, .~
. substituents, compounds, combination agents and the like, that are present or;
' add~d~, depending on the context. Such techniques and knowledge are well ..' ~ .
known within the skills of the concerned artisan.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The term "isolated" or "in isolated form" for a compound refers'to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. The term "purified" or "in purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atoms) to satisfy the valences.

When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W.
Greene et al, Protective Groups in organic Synthesis (1991 ), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula 1, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemp.lated.herein. The term °'prodrug", as employed herein, denotes a compound .that is a drug precursor which, upon administration to a subject, :
.
undergoesvGhemical conversion by metabolic or chemical processes to yield a .
compound of Formula 1 or a salfi and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.
"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H20.

"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the CDK(s) and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
5 The compounds of Formula 1 can form salts which are also within the scope of this invention. Reference to a compound of Formula 1 herein is understood to include reference to salts thereof, unless otherwise indicated.
The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic 10 and/or organic bases. In addition, when a compound of Formula 1 contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically 15 acceptable) salts are preferred, although other salts are also useful.
Salts of the compounds of the Formula 1 may be 'formed, for example, by reacting a -corripound of Formula 1 with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
20 Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, 25 tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) 30 Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66 1 1-19; P. Could, International J. of Pharmaceutics (1986) 33 201-217;
Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present, compounds include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C~_4alkyl, or C~_4alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C~_2o alcohol or reactive derivative thereof, or by a 2,3-di (C6_24)acyl glycerol.
Compounds of Formula 1, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.

All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate"
"prodrug" and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the.inventive compounds.
Polymorphic forms. of the compounds o~ Formula I, and of the salts, solvates, esters and prodrugs of the: compounds of Formula I, are intended to be included in the present invention:.
It is to be understood that the utility of the compounds of Formula 1 for the therapeutic applications discussed herein is applicable to each compound by itself or to the combination or combinations of one or more compounds of Formula 1 as illustrated, for example, in the next immediate paragraph. The same understanding also applies to pharmaceutical compositions) comprising such compound or compounds and methods) of treatment involving such compound or compounds.
The compounds according to the invention can have pharmacological properties; in particular, the compounds of Formula 1 can be inhibitors of HCV
protease, each compound by itself or one or more compounds of Formula 1 can be combined with one or more compounds selected from within Formula 1. The compounds) can be useful for treating diseases such as, for example, HCV, HIV, (AIDS, Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C virus (HCV) protease, preventing HCV, or ameliorating one or more symptoms of hepatitis C.
The compounds of Formula 1 may be used for the manufacture of a medicament to treat disorders associated with the HCV protease, for example, the method comprising bringing into intimate contact a compound of Formula 1 and a pharmaceutically acceptable carrier.
In another embodiment, this invention provides pharmaceutical compositions comprising the inventive compound or compounds as an active ingredient. The pharmaceutical compositions generally additionally comprise at least one pharmaceutically acceptable carrier diluent, excipient or carrier (collectively referred to herein as carrier materials). Because of their HCV
inhibitory activity, such pharmaceutical compositions possess utility in treating hepatitis C and related disorders.
In yet another embodiment, the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive compounds as an active ingredient. In the pharmaceutical compositions and '°~s methods of the present invention, the actie~e ingredients will typically be .
, administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i:e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition.
Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like.
Sweetening and flavoring agents and preservatives may also be included where appropriate. Some of the terms noted above, namely disintegrants, diluents, lubricants, binders and the like, are discussed in more detail below.
Additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic efFects, i.e. HCV inhibitory activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or ,. 15 capsules containing such impregnated or encapsulated porous polymeric matrices.
Liquid form preparations include solutions, suspensions and emulsions.
As;an example may be mentioned water or water-propylene glycol solutions .
for parenteral injections or addition of sweeteners and pacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing.
The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally.
The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
5 The compounds of the invention may also be administered orally, intravenously, intranasally or subcutaneously.
The compounds of the invention may also comprise preparations which are in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active 10 components, e.g., an effective amount to achieve the desired purpose.
The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 1.0 milligram to about 1,000 milligrams, preferably from about 1.0 to about 950 milligrams, more preferably from about 1.0 to about 500 milligrams, and typically from 15 about 1 to about 250 milligrams, according to the particular application.
The actual dosage employed may be varied depending upon the patient°s age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art. v Generally, the human oral dosage form containing the active 20 ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician. A generally recommended daily dosage regimen for oral administration may range from about 1.0 milligram to about 1,000 milligrams per day, in single or divided doses.
25 Some useful terms are described below:
Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients. Hard shell capsules are typically made of blends of relatively high gel strength bone and 30 pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
Oral gel- refers to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.
Powder for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.
Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.
Disintegrant - refers to materials added to the composition to help it -.::: beak apart (disintegrate) and release the medicaments: Suitable ":disinteg.rants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust ::bean, karaya, guar, tragacanth and agar; cellulose derivatives such as . . .
methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.
Binder - refers to substances that bind or "glue" powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate. The amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.
Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'I-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.2 to about 5%
by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.
. . vC~iid~ent - material that prevents caking and improve the flow ~ .
characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the , . .
. , composition can range from about 0.1 % to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.
Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5%
by weight of the composition, preferably from about 0.1 to about 1 %.
Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures. Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.
Another embodiment of the invention discloses the use of the inventive compounds or pharmaceutical compositions disclosed above for treatment of diseases such as, for example, hepatitis C and the like. The method comprises administering a therapeutically effective amount of the inventive compound or pharmaceutical composition to a patient having such a disease or diseases and in need of such a treatment.
In yet another embodiment, the compounds of the invention may be used for the treatment of HCV in humans in monotherapy mode or in a combination therapy (e.g., dual combination, triple combination etc.) mode such as, for example, in combination with antiviral and/or immunomodulatory agents. Examples of such antiviral and/or immunomodulatory agents include Ribavirin (from Schering-Plough Corporation, Madison, New Jersey) and LevovirinT"" (from ICN Pharmaceuticals, Costa Mesa, California), VP 50406TM
(from Viropharma, ~lr~corporated, Exton, Pennsylvania), ISIS 14803TM (from ,.
ISIS Pharmaceuticals, Carlsbad, California), Hepta~ymeTM (from Ribozyme ' w Pharmaceuticals; Boulder, Colorado), VX 497T"" (from Vertex Pharmaceuticals, Cambridge, Massachusetts), Thymosin'~~ (from SciClone Pharmaceuticals, San Mateo, California), MaxamineTM (Maxim Pharmaceuticals, San Diego, California), mycophenolate mofetil (from Hoffman-LaRoche, Nutley, New Jersey), interferon (such as, for example, interferon-alpha, PEG-interferon alpha conjugates) and the like. "PEG-interferon alpha conjugates" are interferon alpha molecules covalently attached to a PEG molecule. Illustrative PEG-interferon alpha conjugates include interferon alpha-2a (RoferonT"", from Hoffman La-Roche, Nutley, New Jersey) in the form of pegylated interferon alpha-2a (e.g., as sold under the trade name PegasysTM), interferon alpha-2b (IntronTM, from Schering-Plough Corporation) in the form of pegylated interferon alpha-2b (e.g., as sold under the trade name PEG-IntronTM), interferon alpha-2c (Berofor AIphaTM, from Boehringer Ingelheim, Ingelheim, Germany) or consensus interferon as defined by determination of a consensus sequence of naturally occurring interferon alphas (InfergenT"", from Amgen, Thousand Oaks, California).

As stated earlier, the invention includes tautomers, rotamers, diastereomers, enantiomers and other stereoisomers of the inventive compounds also. Thus, as one skilled in the art appreciates, some of the inventive compounds may exist in suitable isomeric forms. Such variations are contemplated to be within the scope of the invention.
Another embodiment of the invention discloses a method of making the compounds disclosed herein. The compounds may be prepared by several techniques known in the art. Illustrative procedures are outlined in the following reaction schemes. The illustrations should not be construed to limit the scope of the invention which is defined in the appended claims.
Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.
It is to be understood that while the following illustrative schemes describe the preparation of a few representative inventive compounds, suitable substitution of any of both the natural and unnatural amino acids will result in the formation of the desired compounds based on such substitution.
Such variations are contemplated to. be within the scope of the invention.
Abbreviations . . ,. , .
Abbreviations which are used in the descriptions of the schemes, a .
preparations and the examples that follow are:
THF: Tetrahydrofuran DMF: N,N-Dimethylformamide EtOAc: Ethyl acetate AcOH: Acetic acid HOOBt:3-Hydroxy-1,2,3-benzotriazin-4(3H)-one EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride NMM: N-Methylmorpholine ADDP: 1,1'-(Azodicarbobyl)dipiperidine DEAD: Diethylazodicarboxylate MeOH: Methanol EtOH: Ethanol Et20: Diethyl ether DMSO: Dimethylsulfoxide HOBt: N-Hydroxybenzotriazole PyBrOP: Bromo-tris-pyrrolidinophosphonium hexafluorophosphate DCM: Dichloromethane DCC: 1,3-Dicyclohexylcarbodiimide TEMPO: 2,2,6,6-Tetramethyl-1-piperidinyloxy 5 Phg: Phenylglycine Chg: Cyclohexylglycine Bn: Benzyl Bzl: Benzyl Et: Ethyl 10 Ph: Phenyl iBoc: isobutoxycarbonyl iPr: isopropyl tBu or But: tert-Butyl Boc: tent-Butyloxycarbonyl 15 Cbz: Benzyloxycarbonyl Cp: Cylcopentyldienyl Ts: p-toluenesulfonyl Me: Methyl HATU: O-(7-azabenzotriazol-1-yl)-1,~1.,3y3-tetramethyluronium 20 hexafluorophosphate DMAP: 4-N,N-Dimethylaminopyridine BOP : Benzotriazol-1-yl-oxy-tris(dimethylamino)hexafluorophosphate PCC: Pyridiniumchlorochromate KHMDS: Potassium Hexamethyldisilazide or Potassium 25 bis(trimethylsilylamide) NaHMDS: Sodium Hexamethyldisilazide or Sodium bis(trimethylsilylamide) LiHMDS: Lithium Hexamethyldisilazide or Lithium bis(trimethylsilylamide) 10% Pd/C: 10% Palladium on carbon (by weight).
TG: Thioglycerol General Schemes for Preparation of Target Compounds Compounds of the present invention were synthesized using the general schemes (Methods A-E) described below.

Method A
Deprotection of the N-Boc functionality of 1.01 under acidic conditions provided the hydrochloride salt 1.02 which was subsequently coupled with N-Boc-tert-leucine under peptide coupling methodology to afford 1.03. N-Boc deprotection followed by treatment with appropriate isocyanate gave the urea 1.05. Hydrolysis of the methyl ester provided the acid 1.06. Peptide coupling of the acid 1.06 with the appropriate P1-P' primary amide moiety afforded the hydroxyl amide 1.07. Oxidation (Moffatt oxidation or related process - see, T.
T. Tidwell, Synthesis, 1990, 857), or Dess-Martin Periodinane - J. Org.
Chem., (1983) 48, 4155) resulted in the target compound 1.08.
V V
V
~OCH3 ~OCH3 -..> ~CO~CH3 \/O N O O
O"O O H.HCI
O
1.02 1.03 1.01 V V
'~OCH3 .-' . N' OCH3 H H
HCLHZN~ O ~N N~ O
O ' .Cap ~ 01.05 1.04 V V
OH
.~OH .~N NHZ
Cap'N~N~O O ~ C ~N~N~N O ~O[ O
P
O ~ O
1.06 1.07 V
/~ H O
~N NHS
Ca 'N~N~O 10I O
P
O
1.08 Method B
Peptide coupling of the acid 1.06 with the appropriate P1-P' secondary amide moiety afforded the hydroxyl amide 1.09. Oxidation (Moffatt or Dess-Martin's) resulted in the target compound 1.10.

V V
H OH H
~OH ~N N~
N N II
Cap'N~N~O O Cap'N~N~O O O
O ~ 1.06 IO 1.09 V
H O H
~N N
N
Cap'N~N~O O O
O
1.10 Method C
In another variation, peptide coupling of the N-Boc-P2-P3-acid 1.17 with the appropriate P1-P' amide moiety afforded the hydroxyl amide 1.11.
Oxidation (Moffatt or Dess-Martin Periodinane) resulted in the keto amide 1.12. Deprotection of the N-Boc functionality gave the hydrochloride salt 1.13.
Treatment with a suitable isocyanate (or isocyanate equivalent) resulted in the target compound 1.14.
~/ ~/
.. Fl on H
H .~oH ~ ~~.N. .~~l~N'~" .
~O~N~O O --~ ~O~N~O O O
1.17 O
1.11 V V
H O H ~v H O H
~N N.P, ~N N.P, O~N~I~ O ~O O ~ HCLH2N~0 10I O
O
1.12 ~ 1.13 ~ H O H
"cap-NCO" ~N N,P, or ' Ca ~N N~O IO O
equivalent p 1.14 Method D
In yet another variation, the hydrochloride salt 1.13 was converted to the 4-nitrophenyl carbamate 1.15 by reaction with 4-nitrophenyl chloroformate.
Subsequent treatment with an amine (or amine hydrochloride salt) of choice provided the target compound 1.14.

V V
.. H O H ~ H O H
~N N.P, ~N N,P, HCLHZN~O [O O ~ O~N~O IOI O
OzN I / O
1.13 ~ 1.15 H O H
~~ca~ H H ~N N.P
Ca 'N~N~O O O
P
O
1.14 Method E
In yet another variation, the dipeptide hydrochloride salt 1.03 was converted to the 4-nitrophenyl carbamate as described above. Treatment with an amine (or amine hydrochloride salt) of choice provided the urea derivative 1.05. Hydrolysis and further elaboration as described in Methods A/B
provided the target compounds 1.14.
V V
'~OCH3 '~OGH~
HCLHZN~O O " ~ O~N~N O ~O
1.04 OzN I ~ O ~ 1.16 V V
H O H
"cap-NH2" N OCH3 as above N N N.P, -.
-> H H- ~~ Method A H H
Cap'N~N~O O ( ) Cap'N~N~O O O
O ~ 1.05 IO ~ 1.14 Preparation of P1-P' moieties Preparation of Intermediates 10.11 and 10.12 Steh 1.
o O
HN
W N~OCzHs z OCzHs 10.01 10.02 A stirred solution of ketimine 10.01 (50 g, 187.1 mmol) under N2 in dry THF (400 mL) was cooled to -78 °C and treated with 1 M solution of K-tBuO

(220 mL, 1.15 equiv.) in THF. The reaction mixture was warmed to 0 °C
and stirred for 1 h and treated with bromomethyl cyclobutane (28 mL, 249 mmol).
The reaction mixture was stirred at room temperature for 48 h and concentrated in vacuo. The residue was dissolved in Et20 (300 mL) and treated with aq. HCI (2 M, 300 mL) The resulting solution was stirred at room temperature for 5 h and extracted with Et20 (1 L). The aqueous layer was made basic to pH ~12-14 with NaOH (50 % aq.) and extracted with CH2CI2 (3x300 mL). The combined organic layers were dried (MgS04), filtered, and concentrated to give the pure amine (10.02, 18 g) as a colorless oil.
Step 2.

HaN~OC2H5 BocHN OH
10.02 10.03 A solution of the amine 10.02 (18g, 105.2 mmol) at 0 °C in CH2CI2 (350 mL) was treated with di-terf-butyldicarbonate (23 g, 105.4 mmol) and stirred at rt. for 12 h. After the completion of the reaction (TLC), the reaction mixture was concentrated in vacuo and the residue was dissolved in THF/H20 (200 ml, 1:1 ) and treated with LiOH~H20 (6.5 g, 158.5 mmol) and stirred at room '..
temperature for 3 h. The reaction mixture was concentrated and the basic aqueous layer was extracted with Et20. The aqueous layer was acidified with conc. HCI to pH~1-2 and extracted with CH2C12. The combined organic layers were dried (MgS04), filtered, and concentrated in vacuo to yield 10.03 as a colorless viscous oil which was used for the next step without any further purification.
Step 3.

BocHN OH ~ BocHN N~OMe i Me a 10.03 10.04 A solution of the acid 10.03 (15.0 g, 62 mmol) in CH2CI2 (250 mL) was treated with BOP reagent (41.1 g, 93 mmol), N-methyl morpholine (27 mL), N,O-dimethyl hydroxylamine hydrochloride (9.07 g, 93 mmol) and stirred overnight at rt. The reaction mixture was diluted with 1 N aq. NCI (250 mL), and the layers were separated and the aqueous layer was extracted with CH2C12 (3x300 ml). The combined organic layers were dried (MgS04), filtered and concentrated in vacuo and purified by chromatography (Si02, EtOAc/Hex 2:3) to yield the amide 10.04 (15.0 g) as a colorless solid.
5 Step 4.

BocHN N~OMe BocHN H
i Me U
10.04 10.05 A solution of the amide 10.04 (15 g, 52.1 mmol) in dry THF (200 mL) was treated dropwise with a solution of LiAIH4 (1 M, 93 mL, 93 mmol) at 0 °C.
The reaction mixture was stirred at room temperature for 1 h and carefully 10 quenched at 0 °C with a solution of KHS04 (10% aq.) and stirred for 0.5 h.
The reaction mixture was diluted with aq. NCI (1 M, 150 mL) and extracted with CH2C12 (3x200 mL), The combined organic layers were washed with aq.
HC1~ (1 M),vsaturated NaHC03, brine, and dried (MgS04). The mixture was . . "
v filtered end concentrated in vacuo to yield 10.05 as a viscous colorless oil (14 1.5 g).
Step:
O OH
BocHN H BocHN CN
U
10.05 10.06 A solution of the aldehyde 10.05 (14 g, 61.6 mmol) in CH2C12 (50 mL), was treated with Et3N (10.73 mL, 74.4 mmol), and acetone cyanohydrin 20 (10.86 g, 127.57 mmol) and stirred at room temperature for 24 hrs. The reaction mixture was concentrated in vacuo and diluted with aq. HCI (1 M, 200 mL) and extracted into CH2C12 (3x200 mL). The combined organic layer were washed with H20, brine, dried (MgS04), filtered, concentrated in vacuo and purified by chromatography (Si02, EtOAc/Hex 1:4) to yield 10.06 (10.3 g) as a 25 colorless liquid Step 6.

OH _ + OH
BocHN CN CIH3N OCH3 O
10.06 10.07 Methanol saturated with HCI*, prepared by bubbling HCI gas through CH30H (700 ml) at 0 °C, was treated with the cyanohydrin 10.06 and heated to reflux for 24 h. The reaction was concentrated in vacuo to yield 10.07, which was used in the next step without purification.
* Alternatively 6M HCI prepared by addition of AcCI to dry methanol can also be used.
Step 7.
+ OH OH
CIH3N OCH3 BocHN OCH3 O -t O
U
10.07 10.08 ~ A solution of the amine hydrochloride 10.07 in CHzCl2 (200 mL) was .
treated with Et3f~ (45.0 mL, 315 mmol) and Boc2O (45.7g, 209 mmol) at -78 ~ ?
°C. The reaction mixture was then stirred at room temperature overnight and :~.
diluted with HCI (2 M, 200 mL) and extracted into CH2CI2, The combined organic layers were dried (MgS04) filtered, concentrated in vacuo and purified by chromatography (EtOAc/Hex 1:4) to yield hydroxy ester 10.08.
Step 8.
OH OH
BocHN OCH3 BocHN OH
II ~ II
O O
U
10.08 10.09 A solution of methyl ester 10.08 (3g, 10.5 mmol ) in THF/H20 (1:1 ) was treated with LiOH~H20 (645 mg, 15.75 mmol) and stirred at rt. for 2 h. The reaction mixture was acidified with aq HCI (1 M, 15 mL) and concentrated in vacuo. The residue was dried in vacuum to afford 10.09 in quantitative yield.
Step 9 OH OH
BOCHN OH BocHN NHS
n --- n O O
a 10.09 10.10 A solution of the acid 10.09 (from above) in CH2CI2 (50 mL) and DMF
(25 mL) was treated with NH4CI (2.94 g, 55.5 mmol), EDCI (3.15 g, 16.5 mmol), HOOBt (2.69 g, 16.5 mmol), and NMM (4.4 g, 44 mmol). The reaction mixture was stirred at room temperature for 3 d. The solvents were removed under vacuo and the residue was diluted with aq. HCI (250 mL) and extracted with CH2C1~. The combined organic layers were washed with aq. saturated NaHC03, dried (MgS04) filtered concentrated in vacuo to obtain 10.10, which was used as it was in the following steps. (Alternatively 10.10 can also be obtained directly by the reaction of 10.06 (4.5 g, 17.7 mmol) with aq. H202 (10 mL), LiOH~H20 (820 mg, 20.8 mmol) at 0 °C in 50 mL of CH30H for 0.5 h.).
Step 10.
OH. ~ _ + . OH
BocHN ,~NH~ CIH3N~~NH' COI ---~ . ~O
10.10 10.11 A solution of 10.10 obtained in the previous step was dissolved in 4 N
HCI in dioxane and stirred at rt. for 2 h. The reaction mixture was concentrated in vacuo to give the intermediate 10.11 as a solid, which was used without further purification.
Step 11.
OH _ + OH H
BocHN OH CIH3N N
' O
O
U
10.09 10.12 The required intermediate 10.12 was obtained from compound 10.09 using essentially the procedures described above in Steps 9, 10 with appropriate reagents.
Preparation of Intermediate 11.01 Step 1 OH COZtBu 11.03 11.02 To a solution of 4-pentyn-1-ol, 11.02 (4.15g; Aldrich) was added Dess-Martin Periodinane (30.25g; Aldrich) and the resulting mixture was stirred for 45min. before the addition of (tert-Butoxycarbonylmethylene)triphenylphosphorane (26.75g; Aldrich). The resulting dark reaction was stirred overnight, diluted with EtOAc), washed with aq. sodium sulfite. sat. aq. NaHCO3, water, brine and dried. The volatiles were removed under reduced pressure and the residue was purified by silica gel column chromatography using 1 % EtOAc in hexanes as eluent to give the desired compound, 11.03 (3.92g). Some impure fractions were also obtained but set aside at this time.
Step 2 co2tBu co~tBu / . CBZNH' 'OH
11.03 1 I I 11.04 Using the alkene 11.03 (1.9g) in n-propanol (20m1; Aldrich)), benzyl carbamate (4.95g; Aldrich) in n-propanol (40m1), NaOH (1.29g) in water (79m1), tent-butyl hypochlorite (3.7m1), (DHQ)2PHAL (0.423g; Aldrich)) in n-propanol (37.5m1), and potassium osmate:dehydrate (0.1544g; Aldrich) and the procedure set forth in Angew. Chem. Int. Ed. Engl (1998), 35, (23/24), pp.
2813-7.gave a crude product which was purified by silica gel column chromatography using EtOAc:Hexanes (1:5) to give the desired amino alcohol 11.04 (1.37g, 37%) as a white solid.
Step 3 COztBu COZH
CBZNH'' 'OH CBZNH'' 'OH
11.04 ~ ~ 11.05 To the ester 11.04 (0.700g) was added 4M HCI in dioxane (20m1;
Aldrich) and the resulting mixture was allowed to stand at room temperature overnight. The volatiles were removed under reduced pressure to give the acid 11.05 (0.621 g) as a white solid.
Step 4 CBZHN~ OH H
~OH CBZNH~N~
O
11.05 ~~ 11.01 BOP reagent (3.65g; Sigma) followed by triethylamine (3.45m1) were added to a dichloromethane (20m1) solution of the carboxylic acid 11.05 (2.00g) and allyl amine (0.616m1) at room temperature and the resulting mixture was stirred overnight. The reaction mixture was partitioned between EtOAc and 10% aq. NCI. The organic phase was separated, washed with sat.
aq. sodium bicarbonate, water, dried (magnesium sulfate). The crude reaction product was purified by silica gel column chromatography using (EtOAc:Hexanes; 70:30) as eluent to provide the,~.desired amide 11.01 ('1.73c~) as a viscous yellow oil.
Preparation of Intermediates 12.03 and 12.04 J
Step 1 O OH
BocHN BocHN OH
'OH
O
U
12.01 12.02 Compound 12.01 was converted to the required material 12.02 using essentially the procedures described for Intermediate 10.11, Steps 3-8.
Step 2 OH OH
BocHN OH HCLHZN NHZ
II ~ II
O O
U
12.02 12.03 Compound 12.02 was converted to the required intermediate 12.03 using essentially the procedures described for Intermediate 10.11, Steps 9, 10.
Step 3 .

OH OH H
BocHN OH HCLHZN N
II II
O O
U
12.02 12.04 Compound 12.02 was converted to the required intermediate 12.03 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 13.01 5 Step 1 OH
OzN~ ~ OZN OH
13.02 O
13.03 To a stirred solution of 1-nitrobutane, 13.02 (16.5 g, 0.16 mol) and glyoxylic acid in H20 (28.1 g, 0.305 mol) and MeOH (122 mL) at 0°C-5°C, was added dropwise triethylamine (93 mL, 0.667 mol) over 2 hrs. The solution 10 was warmed to room temperature, stirred overnight and concentrated to dryness to give an oil. The oil was then dissolved in H~O~.:and acidified to pH
=f with 10°~o HCI, followed by extraction vditf~ Et0/~c.vTl~~ cori'-~bined organic .
solution was washed with brine, dried over f~a2S04, filtered and concentrated.
to dryness to give the product 13.03 (28.1 g, 99% yield.
15 Step 2 OH OH
O~N OH HzN OH
O O
13.03 13.04 To a stirred solution of compound 13.03 (240 g, 1.35 mol) in acetic acid (1.25 L) was added 10% Pd/C (37 g). The resulting solution was hydrogenated at 59 psi for 3 hrs and then at 60 psi overnight. The acetic acid 20 was then evaporated and azeotroped 3 times with toluene, then triturated with MeOH and ether. The solution was then filtered and azeotroped twice with toluene to afFord 13.04 as an off white solid (131 g, 0.891 mol, 66%).
Step 3 OH OH
HEN OH BocHN OH
O O
13.04 13.05 To a stirred solution of the amino acid 13.04 (2.0 g, 13.6 mmol) in dioxane (10 mL) and H20 (5mL) at 0°C, was added 1 N NaOH solution (4.3 mL, 14.0 mmol). The resulting solution was stirred for 10 minutes, followed by addition of di-t-butyldicarbonate (0.110 g, 14.0 mmol) and stirred at 0°C for 15 minutes. The solution was then warmed to room temperature, stirred for 45 minutes and kept at refrigerator overnight and concentrated to dryness to give a crude material. To the solution of this crude material in EtOAc (100 mL) and ice, was added KHS04 (3.36 g) and H20 (32 mL) and stirred for 4-6 minutes.
The organic layer was then separated and the aqueous layer was extracted twice with EtOAc and the combined organic layer was washed with water, brine, dried over Na2S04, filtered and concentrated to dryness to give the product 13.05 as a clear gum (3.0 g, 89°l° yield).
Step 4 OH OH
BocHN (OH HCLHZN N
O O
13.05 13.01 Compound 13.05 was converted to the required intermediate 13.01 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 14.01 Step 1 OH
02ND ~ BocHN OH
O
14.02 14.03 Compound 14.02 was converted to the required material 14.03 using essentially the procedures described for Intermediate 13.01, Steps 1-3.
Step 2 OH OH H
BocHN OH HCLHZN N
O O
14.03 14.01 Compound 14.03 was converted to the required intermediate 14.01 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 15.01 Step 1 I~CF3 ~ OzN~CF3 15.02 15.03 To a suspension of silver nitrite (9 g, 58.5 mmol) in diethyl ether (25 mL) at 0°C was added a solution of 4-iodo-1,1,1-trifluorobutane, 15.02 (10 g, 42.0 mmol) in diethyl ether (25 mL) slowly through an addition funnel (approx.
15 min). The resulting mixture was vigorously stirred at 0°C and warmed to rt.
After 50 h, the solid material was filtered off through a celite pad. The resulting diethyl ether solution was concentrated in vacuo to give 15.03 as colorless oil, which was used without further purification.
Step 2, OH
OzN~'CF3 -' BocHN OH
15.03 O
~F3 15.04 Compound 15.03 was converted to the required material 15.04 using essentially the procedures described for Intermediate 13.01, Steps 1-3.
Step 3 OH OH H
BocHN OH HCLHZN N
O O

15.04 15.01 Compound 15.04 was converted to the required intermediate 15.01 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 16.01 O OH H
BocHN~OH ~ HCLHZN~N~
FzC JT F2CJ ~O
16.02 16.01 The acid 16.02 (Winkler, D.; Burger, K., Synthesis, 1996, 1419) is processed as described above (preparation of Intermediate 10.12) to give the expected intermediate 16.01 Preparation of Intermediate 20.01 H3C~CH3 ~CC2CH3 N
H.HCI
20.01 The amino ester 20.01 was prepared following the method of R. Zhang and J. S. Madalengoitia (J. Org. Chem. 1999, 64, 330), with the exception that the Boc group was cleaved by the reaction of the Boc-protected amino acid with methanolic HCI.
(Note: In a variation of the reported synthesis, the sulfonium ylide was replaced with the corresponding phosphonium ylide).
Prepal°ation of Intermediate 20.04 Step 1 CH3~CH3 O CH3~/CH3 BocHN ~OH OCH3 ~OCH3 O
BocHN
H2C~ O O
20.03 20.02 20.01 A solution of commercial amino acid Boc-Chg-OH, 20.02 (Senn chemicals, 6.64 g, 24.1 mmol) and amine hydrochloride 20.01 (4.5 g, 22 mmol) in CH2C12 (100 mL) at 0 °C was treated with BOP reagent and stirred at rt. for 15 h. The reaction mixture was concentrated in vacuo, then it was diluted with aq. 1 M HCI and extracted into EtOAc (3x200 mL). The combined organic layers were washed with saturated NaHC03 (200 mL), dried (MgS04), filtered and concentrated in vacuo, and chromatographed (SiO~, EtOAc/Hex 3:7) to obtain 20.03 (6.0 g) as a colorless solid.
Step 2 CH3~CH3 CH3~CH3 N
BocHN~O O ---r BocHN~ O
O
20.03 20.04 A solution of methyl ester 20.03 (4.0 g, 9.79 mmol) in THF/H20 (1:1 ) was treated with LiOH~H20 (401 mg, 9.79 mmol) and stirred at rt. for 3 h. The reaction mixture was acidified with aq. NCI and concentrated in vacuo to obtain the required intermediate, free acid 20.04.
Preparation of Intermediate 20.07 Step 1 O ' ~ , .
BocHN~O~i ~OCH3 + '+/ OCH3 ~ 'N' ~( BocHN~ O

20.06 20.05 20.01 A solution of Boc-tert-Leu 20.05 (Fluka, 5.0 g 21.6 mmol) in dry CH2CI2/DMF (50 mL, 1:1 ) was cooled to 0 °C and treated with the amine salt 20.01 (5.3 g, 25.7 mmol), NMM (6.5 g, 64.8 mmol) and BOP reagent (11.6 g, 25.7 mmol). The reaction was stirred at rt. for 24h, diluted with aq. NCI (1 M) and extracted with CH2C12. The combined organic layers were washed with HCI (aq, 1 M), saturated NaHC03, brine, dried (MgSO~), filtered and concentrated in vacuo and purified by chromatography (Si02, Acetone/Hexane 1:5) to yield 20.06 as a colorless solid.
Step 2 '~OCH3 ~ '~OCH3 BocHN '~'O~O HCLH2N '~'0~O
20.06 20.07 A solution of methyl ester 20.06 (4.0 g, 10.46 mmol) was dissolved in 4M HCI in dioxane and stirred at rt. for 3 h. The reaction mixture was concentrated in vacuo to obtain the amine hydrochloride salt, 20.07 which 5 was used without purification.
Preparation of Intermediate 21.01:
Step 1:
~coZH ~ ~co2tau Boc Boc 21.02 21.03 10 To a stirred solution of EV-Boc-3,4-dehydroproline 21.02 (5.0 g, 23.5 mmol),'di-tern-butyl dicarbonate (7.5 g, 34.4 mmol), and 4~-IV,I~-dimethylaminopyridine (0.40 g, 3.33 mmol) in acetonitrile (100 mL) at room temperature was added triethylamine (5.0 mL, 35.6 mmol). The resulting solution was stirred at this temperature for 18 h before it was concentrated in 15 vacuo. The dark brown residue was purified by flash column chromatography eluting with 10-25% EtOAc/hexane to give the product 21.03 as a pale yellow oil (5.29 g, 84%).
Ste p 2:
cl~cl \ N/ _COZtBu (!~~
'~COZtBu Boc , Boc 21.03 21.04 20 To a stirred solution of the dehydroproline derivative 21.03 (10.1 g, 37.4 mmol), benzyltriethylammonium chloride (1.60 g, 7.02 mmol) in chloroform (120 mL) at room temperature was added 50% aqueous sodium hydroxide (120 g). After vigorously stirred at this temperature for 24 h, the dark mixture was diluted with CH2CI2 (200 mL) and diethyl ether (600 mL).
25 After the layers were separated, the aqueous solution was extracted with CH2C12/Et20 (1:2, 3x600 mL). The organic solution was dried (MgS04) and concentrated. The residue was purified by flash column chromatography using 5-20% EtOAc/hexane to afFord 9.34 g (71 %) of 21.04 as an off-white solid.
Step 3:
c1 ~cl c1 ~cl ~ ---~ ~ ~CF3COZH
I~COztBu '~COzH
Boc H
21.04 21.05 The solution of 21.04 (9.34 g, 26.5 mmol) in CH2C12 (25 mL) and CF3C02H (50 mL) was stirred at room temperature for 4.5 h before it was concentrated in vacuo to give a brown residue, 21.05 which was used in Step 4 without further purification.
Step 4 cl~ci cl~cl n HCI
~ ~CF3COZH ~CO Me '~COZH H z H
21.05 21.01 Concentrated hydrochloric acid .(4.~ mL) was added to a solution of the residue 21.05 from Step 3 in methab~I (70 mL) and the resulting mixture was warmed to 65°C in an oil bath. After 18 h, the mixture was concentrated in vacuo to give a brown oil 21.01, which was used further without purification.
Preparation of Intermediate 22.01 Step 1 tBc~ tBOC~

N CHO Ph3P.-/I N w retl~ux / ' THF

, o O

22.02 22.03 Potassium bis(trimethylsilyl)amide (158m1 of a 0.5M solution in toluene;
79mmol) was added to a stirred suspension of cyclopropyltriphenylphosphonium bromide (33.12g; 86.4mmol) in anhydrous tetrahydrofuran (130m1) and the resulting orange mixture was stirred under an atmosphere of nitrogen at room temperature for a period of 1 h., before the addition of the aldehyde 22.02 (9.68g; 42.2mmol) in THF (8m1). The reaction was then refluxed under an atmosphere of nitrogen for a period of 2h. After cooling, methanol, diethyl ether and Rochelles salt were added. The organic phase was separated, washed with brine, dried and concentrated under reduced pressure. The crude reaction product was purified by silica gel column chromatography using EtOAc-hexane (1:99) to EtOAc-hexane (5:95) to provide the alkene 22.03 (8.47g) as a yellow oil.
Step 2 NHtBoc tBoc~ p N ~ HN
1.HC1(aq) 2. tBoc-Gly-OSu, Et3N H~
22.03 22.04 A solution of 1 M HCI in MeOH/MeOAc was prepared by adding 14.2m1 of acetyl chloride dropwise into cold methanol and diluting the resulting solution to 200m1 at room temperature.
The carbamate 22.03 (9.498; 37.5mmol) was dissolved in methanol (12m1) and added to 1 M HCI in MeOH/MeOAc (150m1) while cooled in an ice bath. The resulting mixture was maintained at this temperature for 1 h., then the ice bath was removed and stirring continued overnight at room temperature. The volatiles were, removed under~reduced pressure to yield a yellow oil which was used in the next step without. purification.
. . , ,. .
The yellow oil was dissolved in a mixture of THF (30m1) and MeOH
(20m1) and treated with triethylamine (15m1; 108mmol) until the solution was pH=9-10. After placing in an ice bath, the mixture was treated with N-Boc-Gly-OSu (11.22g; 41 mmol). The ice bath was withdrawn and the reaction stirred at room temp. for 1 h. The volatiles were removed under reduced pressure and the residue was purified by silica gel column chromatography using methanol (1-3%) in dichloromethane providing the desired amide 22.04 (9.09g).
Step 3 O~NHtBoc O~NHtBoc HN ~ 2,2-dimethoxypropane N
HO ~0 22.04 22.05 The alcohol 22.04 (9.09g; 33.6mmol) was dissolved in acetone (118.5m1) and treated with 2,2-dimethoxypropane (37.4m1;304mmol) and BF3:Et20 (0.32m1; 2.6mmol) and the resulting mixture was stirred at room temperature for a period of 5.5h The reaction solution was treated with a few drops of triethylamine and the volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography using 5-25% EtOAc in hexanes to provide the N,O-acetal 22.05 (8.85g).
Step 4 NHtBoc p _ ~ O
(. NOBF4 ~
2. Pywolidine W 3. Pd(OAc)2 ~~N and S~N
//XX~\ .H .H
O O O
22.05 22.06 22.07 The carbamate 22.05 (8.81 g; 28.4mmol) was dissolved in acetonitrile (45m1) and the solution was cooled to -40°C under an atmosphere of nitrogen. Pyridine (6.9m1; 85.3mmol) followed by nitrosium tetrafluoroborate (6.63g; 56.8mmol) were added and the resulting reaction mixture maintained below 0°C until TLC indicated that no starting material r~e~ained (approx.
2.25h.). Pyrrolidine (20m1; 240mmol) was added and the. cooling bath was withdrawn and stirring was continued at r~om temperature for 1 h. and then the volatiles eNere removed under reduced pressure. The,residue was quickly passed through a pad of silica gel to provide a yellow oil.
The yellow oil was dissolved in anhydrous benzene (220m1) and palladium acetate (0.317g; 1.41 mmol) was added before heating the resulting mixture to reflux, under an atmosphere of nitrogen for a period of 1.5h. After cooling, the volatiles were removed under reduced pressure and the dark residue was purified by silica gel column chromatography using EtOAc-hexane (1:4) to provide the I) the trans- pyrrolidinone 22.06 (1.94g) followed by ii) the cis-pyrrolidinone 22.07 (1.97g).
Step 5 o _~ o _ N HCl in MeOAc/MeOH
i~ .H N .H
O HO
22.06 22.08 Freshly prepared 1 M HCI in MeOAc/MeOH (1 Oml; as described above) was added to the N,O-acetal 22.06 and stirred at room temperature for 1 h.

The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using 0-4%MeOH in dichloromethane as eluent to provide the desired alcohol 22.08 (1.42g), a yellow oil.
Step 6 ° ~ -t. LAH
N 2. N-Boc-L-tert-Leu-OH
'H N
HATU BoctHN 'H
HO ° HO
22.08 22.09 To a solution of the lactam 22.08 (1.29g; 8.44mmol) in anhydrous tetrahydrofuran (55m1) was added lithium aluminum hydride (2.40g;
63.2mmol) and the resulting mixture was refluxed for 8h. After cooling, water, followed by 15% aq. NaOH were added and the resulting mixture was filtered through celite and the solid was washed thoroughly with THF and MeOH. The solvent was removed under reduced pressure and the residue redissolved in dichloromethane, dried and concentrated under reduced pressure to provide the pyi-rolidine, used without purification.
Hunigs base (4.5m1; 25.8mmol) was added to admixture of N-Soc-L-tert-Leu-OH (1.76g; 7.6mmol), The crude pyrrolidine and HATU (2.89g;
7.6mmol) in anhydrous dichloromethane (50m1) at -60°C, under an atmosphere of nitrogen. The resulting reaction was allowed to come to room temperature slowly, overnight. EtOAc was added and the yellow solution was washed with dil.aq. NCI, sat. aq. sodium bicarbonate, water, brine. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EtOAc:hexanes (1:3) to give the desired amide 22.09 (2.00g).
St-e~7 _~ _ Jones , N N
tBocHN 'H tBocHN
O HO O COZH
22.09 22.01 The alcohol 22.09 (2.00g; 5.67mmol) was dissolved in acetone (116m1) and cooled in an ice bath for 10min. This solution was then added to a cooled Jones reagent (14.2m1; approx 2mmol/ml) and the resulting mixture was stirred at 5°C for 0.5h and the cooling bath was removed. The reaction 5 was stirred for a further 2h. at room temp., before adding to sodium sulfate (28.54g), celite (15g) in EtOAc (100m1). Isopropanol (15m1) was added after 1 min and then stirred for a further 10min. and filtered. The filtrate was concentrated under reduced pressure, providing a brown oil which was dissolved in EtOAc. This solution was washed with water, 3% aq. citric acid, 10 brine, dried and concentrated to provide the desired carboxylic acid 22.01 (1.64g) as a white solid.
Preparation of Intermediate 23.01 Step 1:

~OCH3 ~ , ms 4A°
H
~~O O
23.02 15 To the mixture of ester 23.02 (6.0g) and molecular sieve (5.2g) in anhydrous methylene chloride (35 mL) was added pyrrolidine (5.7 mL, 66.36 mmoL). The resulting brown slurry was stirred at room temperature under N2 for 24 h, filtered and washed with anhydrous CH3CN. The combined filtrate was concentrated to yield the desired product, 23.03.
20 Steh 2:
~ci Nal, K~C03 GJ.VJ
To a solution of the product 23.03 from proceeding step in CH3CN (35 mL) was added anhydrous K2C03, methallyl chloride (2.77g, 30.5 mmoL), Nal (1.07g, 6.7 mmoL). The resulting slurry was stirred at ambient temperature 25 under N2 for 24 h. 50 mL of ice-cold water was added followed by 2N KHS04 solution until pH was 1. EtOAc (100 mL) was added and the mixture was stirred for 0.75h. Combined organic layer was collected and washed with brine, dried over MgS04, and evaporated to yield the desired product, 23.04.
Step 3:
1 N LiOH / dioxane The product 23.04 from the preceding step (2.7 g, 8.16 mmoL) was dissolved in dioxane (20 mL) and treated with freshly prepared 1 N LiOH (9 mL). The reaction mixture was stirred at ambient temperature under N2 for 20 h. The reaction mixture was taken in EtOAc and washed with H20. The combined aqueous phase was cooled to 0°C and acidified to pH 1.65 using 1 N HCI. The turbid mixture was extracted with EtOAc (2 x 100 mL).
Combined organic layer was washed with brine, dried over MgS04, and concentrated to give the desired acid, 23.05 (3.40 g).
Step ~:
NaBH(OAc)3 c~.vo To a suspension of NaBH(OAc)3 (3.93g, 18.5 mmoL) in CH2CI2 (55 mL) was added a solution of product 23.05 from preceding step in anhydrous CH2CI2 (20 mL) and acetic acid (2 mL). The slurry was stirred at ambient temperature for 20 h . Ice cold water (100 mL) was added to the slurry and stirred for 1/2 hr. Organic layer was separated, filtered, dried and evaporated to yield the desired product, 23.06.
Step 5:
HO,, ~OH CHzN2l Et20 / MeOH
N
~ O
O"O
L3.V I
23.06 To a solution of the product 23.06 from preceding step (1.9g) in MeOH
(40 mL) was treated with excess of CH2N2 / Et20 solution and stirred for overnight. The reaction mixture was concentrated to dryness to yield a crude residue. The residue was chromatographed on silica gel, eluting with a gradient of EtOAc / hexane to afford 1.07 g of the pure desired product, 23.07.
Step 6:
Ho,, OMe OMe BF3 . Me O / CH CI N

\ O OO \ O OO
23.08 23.07 To a solution of product 23.07 from preceding step (1.36 g) in anhydrous CH2CI2 (40 mL) was treated with BF3. Me20 (0.7 mL). The reaction mixture was stirred at ambient temperature for 20 h and quenched with sat. NaHC03 (30 mL) ad stirred for 1/2 hr. Organic layer was separated and combined organic layer was washed with brine, dried over MgSO4, concentrated to give crude residue. The residue was chromatographed on silica gel eluting with a gradient of EtOAc / hexane to afford 0.88 g of the desired compound, 23.08.
Step 7:
o' 1 0' 1 home Hz -10% Pd /C
N home \ O~O O H 1I0 23.01 23.08 To a solution of the product 23.08 (0.92 g) from preceding step in MeOH (30 mL) was added 10 % Pd/C (0.16 g) at room temperature and hydrogenated at ambient temperature under 1 atm. Pressure. The reaction mixture was stirred for 4 h and concentrated to dryness to yield the desired compound, 23.01.

Preparation of Intermediate 50.01 Step 1 CO~H COZCH3 50.02 50.03 To a solution of 50.02 (15 g) in MeOH (150 mL) was added conc HCI
(3-4 mL) and the mixture was refluxed for 16 h. The reaction mixture was cooled to room temperature and concentrated. The residue was taken in diethyl ether (250 mL) and washed with cold saturated sodium bicarbonate solution, and brine. The organic layer was dried (Na2S04) and concentrated to afford the methyl ester 50.03 (12.98 g) which was carried forward without further purification.
Step 2 OH
50.03 50.04 The methyl ester 50.03 from above was dissolved in methylene chloride (100 mL) and cooled to -78°C, under nitrogen atmosphere. DIBAL
(1.0 ~M solution ~n methylene dhlorid~, 200 mL) was added dropwise over 2 h period. The reaction mixture gas warmed to room temperature over 16 h. The reaction mixture was cooled fo 0°C and MeOH (5-8 mL) was added dropwise.
A solution of aqueous 10% sodium potassium tartarate (200 mL) was slowly added with stirring. Diluted with methylene chloride (100 mL) and separated the organic layer (along with some white precipitate). The organic layer was washed with 1 N HCI (250 mL), brine (200 mL), dried (Na2S04) and concentrated to provide the alcohol 50.04 (11.00 g) as a clear oil.
Step 3 OH CHO
50.04 50.05 The alcohol 50.04 from above was dissolved in methylene chloride (400 mL) and cooled to 0°C under nitrogen atmosphere. PCC (22.2 g) was added in portions and the reaction mixture was slowly warmed to room temperature over 16 h. The reaction mixture was diluted with diethyl ether (500 mL) and filtered through a pad of celite. The filtrate was concentrated and the residue was taken in diethyl ether (500 mL). This was passed through a pad of silica gel and the filtrate was concentrated to provide the aldehyde 50.05 which was carried forward without further purification.
Step 4 CHO HCLH~N~C02H
Me a 50.05 50.01 The aldehyde 50.05 from above was converted to the desired material 50.01 using essentially the method of Chakraborty et. al (Tetrahedron, 1995, 51 (33), 9179-90).
Preparative Example 100:
Preparation of Compound of Formula 100 of Table I
Part I: Preparation of Amine of formula 100-1 H
N~~O
H2~ ~' II
~,. J, 100-1 . . y steps: ~ .....
HO N 0 j~0 N O
Me2S02C1, Pyridine To a 0°C solution of commercially available N-t-BOC-L-Cyclohexylglycinol 100-2 (OmegaChem, Canada) (15g, 62 mmol) in DCM (170 mL) and Pyridine (17 mL) was added dropwise methanesulfonylchloride (5.3 mL, 68 mmol, 1.1 equiv). After addition, the reaction was warmed-up to RT and stirred for 18 hours. The reaction was diluted with EtOAc and washed 2 times with 120 mL
of ice-cold water then brine (100 mL). Organic layer was dried over MgS04, filtered and concentrated down to provide 20.9 g of crude oil 100-3.
Step2:

N O N N O
NaN3, DMF
100-3 65°C 100-4 To a RT solution of 100-3 (3.4g of crude) in DMF (7 mL) was added NaN3 (9.62g) and the reaction was warmed-up to 65°C. After 5hours, reaction was cooled down and diluted with EtOAc (100 mL) and ice-cold water (100 mL).
5 After extraction, organic layer was washed water and with brine, dried over MgS04, filtered and concentrated down to a viscous oil. The residue was purified via HPFC using a 40+M column and 2% to 8% EtOAC in Hexane.
Purification furnished 1.06 g of azide 100-4.
Step3:
N O
N3 ~ Hz, 10%Pd/C HzN N O

10 100-4 MeOH 100-1 To a RT solution of azide 100-4 (1.06g) in MeOi-l (35 mL) was added under N2 atmosphere 100 mg of Pd/C (10%). Reaction was flushed with H2 gas and stirred at RT for 18 hours, then filtered trough a pad of celite and concentrated 15 down to provide 100-1 as a viscous oil (0.85 g).
Part I I: Preparation of Amine of formula 100-5 \N N NHz.HCI

Step 1:

Me2NH, THF
~O O~ EtOH, 0°C to RT ~N

20 To a 0°C solution of commercially available (Sigma-Aldrich) 3,4 Diethoxy-3-cyclobutene-1,2-dione 100-6 (15 mmol, 2.5g) in EtOH (50 mL) was added dropwise 10 mmol of Me2NH (5 mL, 2.0M ion THF). Reaction was gradually warmed-up to RT. After 2 h, reaction was concentrated down and purified via HPFC using a 25+M column and 20% to 60% EtOAC in Hexane. Purification furnished 1.95 g of product 100-7.
Step 2:
H
N \ /O\ /
H2 ~ ~N
o p O O O

H
EtOH, RT \N H N O
DIPEA

To a RT solution of amine 100-1 (250mg, 1.48mmol) in EtOH (5mL) was added cyclobutenedione 100-7 (1.2equiv, 190mg) and DIPEA (0.1 mL).
Reaction was stirred at RT for 1 hour then refluxed overnight. After 18hours , a white precipitate had formed. The reaction was stopped and cooled down.
The white precipitate was filtered off and rinsed with E.t~Ac, dried under N2 flow to yield 445 mg of desired product 100-8.
Step 3:
o ~ o a H CsC03, Mel H
~N H N~O DMF \N N N~O
~'O'~ ~ ~ ~ IOI

To a 0°C solution of amine 100-8 (228 mg, 0.67 mmol) in DMF (10 mL) was added Cs2C03 (1.5 equiv, 1 mmol, 325 mg) followed by Mel (1.8 equiv, 1.2 mmol, 0.075 mL). Reaction was stirred at RT overnight then diluted with EtOAc and water. Aqueous layer extracted with EtOAc again. Combined organic layers were washed with brine and dried over MgS04, filtered and concentrated down. Purification via HPFC using 80% EtOAc in Hexane provided 200 mg of desired 100-9.
Step 4:

O O O O
H HCL 4.0N
\N N N~O Dioxane ~N N NH2.HC1 O
100-9 ~ 100-5 To 30 mg of amine 100-9 (0.1 mmol) was added 3mL of 4.0N HCI in Dioxane.
Reaction was stirred at RT until no starting material was detected. After 1 h, Reaction was concentrated under vacuum to provide amine salt 100-5 as a light yellow solid.
Part II I: Preparation of isocyanate of formula 100-10 OH
'~~O 100-12 ~
N INHBOC ~ Johnes Oxidation ~OH
OH HATU, DCM, DIPEA O OH 0°C O (I0 100-11 ~/~ 100-14 -20°C NHBOC 100-13 NHBOC
OH
HCLHZN~~NH~ ~ . ~/
O OH
12.03 ~ NHZ 1) Moffat Oxidation H
'N . ~ 'N'. .N. NHZ
HATU, DCM, DIPEA ~~O O 0 2) 4.0N HCI l Dioxane ~ O O
-20°C ~ 3). Phosgene, NaHC03 ~~
NHBOC N
100-15 O%C~ 100-10 Step1:
OH
O 100-12 ~pH
N NHBOC ~ Jones Oxidation IIN
H
OH HATU, DCM, DIPEA ' O OH 0°C O O

-20°C NHBOC 100-13 NHBOC
To a -20°C solution of Amine 100-11 (10g, 72mmol) prepared following the method of R. Zhang and J. S. Madalengoitia (J. Org. Chem. 1999, 64, 330) in DCM (200mL) was added HATU (1.05equiv, 28.8g), Boc-L-TertLeucine 100-12 (Aldrich Chemical Co.,Milwaukee, Wisconsin, USA, 1.1 equiv,79.2 mmol, 18.3g) and DIPEA (0.2 mol, 40 mL). Reaction was stirred for 24h then was diluted with EtOAc and washed with NaHC03. Organic layer was washed with citric acid then brine. Organic layer was dried over MgS04, filtered and concentrated under vacuo. The residue 100-13 (72 mmol) was dissolved in Acetone (1.2 L) at 0°C . Then , 5equiv of Jones reagent (138 mL, 360 mmol,. prepared by dissolving 91 g of Chromium trioxide in 70 mL of conc, H2S04 and diluted to 300 mL) were added. After 45 min, no starting material was detected by TLC. Isopropanol (40 mL) was added and 500 mL of EtOAc.
The green solution was filtered off through a pad of celite and the filtrate concentrated to dryness. The residue was diluted with 10% sodium carbobate and extracted with Et20. The aquous layer was then acidified to Ph=2 with HCI 3.0N and extracted with EtOAc (3 times 200 mL). Organic layer was dried over MgS04, filtered and concentrated under vacuo. to yield 21.55 g of intermediate 100-14.
Step2:
OH
HCLHZN NHZ
OH
12.03 ~ N NHS
N ~ ., HATU, DC;M, DIPEA 0 -20°r NHBOC

To a -20°C solution 100-14 (10.4g, 28mmol) in DCM (300 mL) was added HATU (1.05 equiv, 29.4mmol, 11.2g), amine salt 12.03 (1.Oequiv, 28mmol, 5.48g, prepared as described in Preparation of intermediates, preparation of P1-P' moieties). After 10 min at -20°C, DIPEA (3.6equiv, mmol, 17.4mL) was added. Reaction was stirred at this temp for 16 h. After 16, the reaction was diluted with EtOAc and washed successively with NaHC03, citric acid (10% w/w) and brine. Organic layer was dried over MgS04, filtered and concentrated under vacuo to yield: 14 g of intermediate 100-15.
Step3:

O
H
1) MoffatOxidation N N NHZ

2) 4.0N HCI l Dioxane O O ~O
3) Phosgene, NaHC03 N
%C~ 100-10 O
Et3N (3 equiv., 5.2 mmol, 0.72 mL) is added to a mixture of crude 100-15 (1.06g, 1.73 mmol theor.) and EDCI (4equiv., 6.92 mmol, 1.33g) in EtOAc (12 mL) at RT. After addition, DMSO (4.5 mL) was slowly charged. This was followed by addition of methanesulfonic acid (3.6equiv, 6.22 mmol, 0.4 mL) with temperature between 20 and 30°C. The reaction was agitated for 1 h.
After 1 h, TLC shows reaction completed. At 0°C, a chiled mixture of EtOAc (12 mL) and iced water (2 mL) was added. After 2 minutes, the biphasic mixture was allowed to settle and the layers were separated. The upper organic layer was washed with H20 and brine. Organic layer was dried over MgSO4, filtered and concentrated under vacuo. The residue was purified by HPFC, 25-~M, 15% to 60% (EtOAc) in Hexanes. Purification provided (0.6g) of Icetoami,de. To a RT solution ketoamide (0.6g) vu~as added 25mL of a 4:0 N
HCI solution in Dioxane. Reaction was stirred at RT for 1 h to observe completion then concentrated to about 5 mL and diluted with Heptanes and Ether.(10 mL each). The resulting white precipitate was filtered off and dried under a N2 flow to provide 0.49 g (81 % yield) of amine as HCI salt. To a OC
solution of amine salt (50 mg, 0.1 mmol) in CH2C12 (7 mL) was added aquous NaHC03 sat. (7 mL) and phosgene (0.053 mL, 1.1 equiv, 0.11 mmol). Rapid stirring was resumed immediatly and the ice-cooled reaction mixture was stirred for 30 min. at high speed. Then the organic phase (lower) was separated and dried over MgS04 and concentrated to half volume under vacuum with cooling bath. The isocyanate 100-10 was then poured into a cylinder and diluted with CH2C12 to 15 mL and used freshly in the next step (Part IV).
Part IV: Preparation of Compound of Formula 100 of Table I

H O
N~N NHZ
DCM, DIPEA O O ~O

0°C to RT ~ ~ 100 N N
Following general method C: To a 0°C solution of amine 100-5 (33 mg, 0.1 mmol) in CH2CI2 (5 mL) was added isocyanate 100-10 (1 equiv., 0.1 mmol) then DIPEA (0.4 mmol, 0.07 mL). The reaction was stirred at RT for 2 hrs then 5 diluted with EtOAc and washed with sat. NH4C1 and Brine. Organic layer was dried over MgS04, filtered and concentrated to dryness. Residue was purified by plate with 5°l° MeOH in EtOAc to get 9 mg of product of formula 100 (10°l°
yield) ;. LCMS : (712.2 : M+1 ) HC\~ inhibitors 110. 113 and 133 described in Table 1 were prepared using 10 intermediate of formula 100-5 according to the general procedures described before.
Preparative Example 106 Preparation of Compound of Formula 106 of Table I
Part I: Preparation of Amine of formula 106-1 H
N\ /O\ /
H2 ~ ~N
O

Amine 106-1 was prepared according the procedure outlined in preparative example 100 by replacing in step1 the commercially N-t-BOC-L-Cyclohexylglycinol 100-2 with the corresponding commercially available N-t-BOC-L-tert-Butylglycinol.
Part II: Preparation of amine salt of formula 106-2.

NH2.HC1 N N

Amine 106-2 was prepared according the procedure outlined in preparative example 100, part II by replacing in step 2 amine of formula 100-1 by amine of formula 106-1 described before.
Part III: Preparation of compound of formula 106 H O
~N NH2 N
DCM, DIPEA O O ~O

100-10 ~ ~ 0 NH
0°C to RT ~ ~ 106 N. N
Compound of formula 106 was prepared following the procedure outlined in part IV of preparative example 100 by replacing amine 100-5 with amine salt 106-2.
HCV inhibitors 115, 121, 135, 147 and 148 described in Table 1 were prepared using intermediate of formula 106-1 according to the general procedures described before.
Preparative Example 104 Preparation of Compound of Formula 104 of Table I
Part I: Preparation of Amine of formula 104-3 N NHZ,HCI
H

Step 1:

tBu-Li /~o 0 To a solution of commercially available diethyl squarate 104-1 (Aldrich Chemical Co.,Milwaukee, Wisconsin, USA, 1g, 5.88 mmol) in THF (20 mL) at -78°C was added t-BuLi (5.93 mmol, 3.5 mL) over a period of 30 seconds.
After 50 min, 0.5 eq. t-BuLi was added to the reaction and stirring was continued for 60 min at -40°C. Then, TFAA (1 mL, 7.06 mmol) was added at -40°C dropwise. After 10 min, 10% NH4C1 (aqueous) (10 mL ) was added.
The resulting solution was warmed to RT and poured into a mixture of Et20 (50 mL) / 5% NaHC03 (aqueous) (80 mL). The aqueous layer was extracted with ether. Combined organic layer was washed with brine then dried over MgS04. After concentration to dryness, the residue was purified by HPFC, 25+M column with 520% EtOAc in hexane a~ eluent to give 0.8748 product 104-2.
.
Step 2: .
H
N ~O~
H2 ~''~ ~N
o p 1) O O O

N NH2,HC1 EtOH, RT H
DIPEA

2) 4.0 N HCI in Dioxane The procedure for the preparation of intermediate of formula 104-3 is similar to the one used for the preparation of amine 100-1 of preparative example 100 by replacing in step 2 compound of formula 100.7 by compound of formula 104-2. In addition, the procedure for the preparation of amine HCI
salt of formula 104-3 is similar to the one used for the preparation of amine 100-9 in step 4 of preparative example 100.
Part II: Preparation of intermediate of formula 104-4 N ~Ow OMe 1) 4,0 N HCI / Dioxane N
O O

2) Phosgene, NaHC03, DCM
O\/NH O~C'N 104-4 O 20.03 To a room temperature solution (10g) To a RT solution of intermediate of formula 20.03 prepared in step 1 of preparation of intermediate of formula 20.04 (5.4g) was added 50mL of a 4.0 N HCI solution in Dioxane. Reaction was stirred at RT for 18h then concentrated to about 20 mL and diluted with Heptanes and Ether (100 mL
each). The resulting white slurry was filtered off to deliver the desired amine HCL salt as a white powder (3.~2g). The amone~salt (3 g) was added to a 0°C
solution of saturated aqueous NaHC03 (50m1-.), DCM (50mL) and Phosgene (2equiv, 16.8mmol, 8.9mL). Rapid stirring was set immediately and the ice cooled reaction mixture was stirred for 1 hours at high speed. After 1 hours, the organic phase (lower) was separated and was then dried over anhydrous MgS04 and concentrated to about 20 mL under vacuum. Isocyanate was diluted to 34 mL (DCM) and used as a 0.25M solution.
Part III: Preparation of intermediate of formula 104-6 Step1:

NHZ.HCI
N
OMe H OMe N ~ 104-3 ~ N
O
O
O O DCM, DIPEA O O O NH
O~C'N 104-4 H

To a 0°C solution of amine salt 104-3 (1.15g, 4mmol) in DCM (20 mL) was added 1.1 equiv of isocyanate 104-4 (17.6 mL) followed by DIPEA (4equiv, 16mmol 2.8 mL). Reaction was warmed-up to RT and stirred for 1 h then diluted with EtOAc, washed with HCI 1.0N (50 mL) then brine. Organic layer was dried over MgS04, filtered and concentrated down. The residue was purified by HPFC, 25+M, 15 to 60% EtOAc in Hexanes to provide intermediate of formula 104-5 (2.31 g , 3.85 mmol. 96% yield).
Step2:
~OH
N
1 ) CsC03, Mel, DMF O O

2) LiOH l Dioxane O O O~NH
N '~~ ~ 104-6 To a 0°C of intermediate of formula 104-5 (2.31 mg, 3.85 mmol) in DMF
(50mL) was added CsC03 (1.5 equiv, 5.8 mmol, 1.9g) followed by Mel ( 1.8 equiv, 7mmol, 0.5 mL). Reaction was stirred at RT for 2 h when MS shows desired material no starting material left. Reaction was diluted in EtOAc and water. Aquous layer extracted with EtOAc again. Combined organic layers were washed with brine and dried over MgSO4, filtered and concentrated down. Purification by HPFC 40+M, 15% EtOAc to 60% furnished 2.32g (98%) of N-Methyl intermediate. To a 0°C solution of this N-Methyl intermediate (2.3g, 3.7 mmol) in dioxane (30 mL) was added 3equiv of LiOH (1.0N
solution, 11.1 mL). After 2h, TLC showed no starting material. Reaction was diluted with Et20 (100 mL) and 10 mL of 1.0N HCI were added. Organic layer was washed with brine, dried over MgS04 and filtered. Filtrate was concentrated down to provide intermediate of formula 104-6 as a light yellow solid (2g, 90% yield).
Part IV: Preparation of intermediate of formula 104-7 HCI OH ( HZN N J
O
13.01 O O
HATU, DIPEA, DCM
N
V
H OH H
~ 'N N J
N
O I0I ~ 0 O 0 O-' 'NH
~NH 104.7 N
5 .To a -20°C solution of acid 104.6 (0.02mmol, 0.013g) in DCM ,(3 mL) was added HATtJ (1.1 equiv, 0.023mmol, 9 mg), amine 13.01 (from step 4 of preparation of intermediate 13.01, 1.Oequiv, 0.02mmol, 5mg), followed by .
DIPEA (0.02 mL). a Reaction was stirred at -20C for 18h then diluted with EtOAc (10 mL), washed 10 with HCI 1.0N (5 mL) then brine. Organic layer was dried over MgS04, filtered and concentrated down. The residue was purified by preparative plate with 100% EtOAc to provide 10 mg of hydroxy amide 104.7 (65% yield).
Part V: Preparation of compound of formula 104 N O NJ
N' O
Dess-Martin Oxidation 0 O
104.7 O\'NH

NH
N
15 To a RT solution of 104.7 (10 mg, 0.13 mmol) in DCM (3 mL) was added Dess-Martin Reagent (30 mg). After 1 h, MS analysis showed desired material and no starting material left. Reaction was diluted with EtOAc and stirred at RT with a 1/1 (5 mL) mixture of NaHC03aq saturated and Na2S2O3 for 5 min. Phases were separated and organic layer was dried over MgS04, filtered and concentrated down. The residue was purified by preparative plate using 90% EtOAc in Hexane as eluent. Purification furnished 4mg of compound of formula 104.
Preparative Example 112 Preparation of Compound of Formula 112 of Table I
H O
O O N~N NHZ
HCI
NH2 DCM, DIPEA O O ~O
O O

104-2 0°C to RT
N
H
~ 0 Compound.of formula 112 was prepared according preparative example 10~ .~
by,replacing in part III amine of formula 106-2 by amine of formula 104.3"
In addition, HCV inhibitors 103, 107, 109, 111, 114, 117, 119, 123, 123, 137, 140 and 145 described in Table 2 were prepared using intermediate of formula 104-3 according to the general procedures described before.
In addition, amines of formula 101-1, 116-1, 129-1 and 132-1 were prepared in the same manner than amine of formula 104- of preparative example 104 by replacing in step 1, t-BuLi by other reagents like (but not limited to) clopropyl-magnesiumchloride, isopropyl-magnesiumchloride, MeLi, ethyl-magnesium chloride to prepare respectively intermediates of formula 101-1, 116-1, 129-1 and 132-1.

O O O O
NH2,HC1 H NH2,HC1 101-1 ~ 116-1 N NH2,HC1 N NHZ,HCI
H H

HCV inhibitors 101, 105, 116, 118, 120, 122, 124, 125, 129, 130, 131, 132, 134, 136, 143, 144 and 146 described in Table 2 were prepared using intermediate of formula 101-1, 116-1, 129-1 and 132-1 according to the general procedures described before. The Ki* range shown is: Range A: Ki* _<
75 nM; Range B: Ki*> 75 nM.
p C d TABLE 2 MW K~
# Range N NHZ

100 ~ H o 711.9 A
N~NH
I IO

O
' N NH
N_ O O O
101 O O p~NH II 747.0 A
N NH
H O
N~N NH

102 0 o p~NH II 789.0 A
N NH
H O H
N~N N
O O O
103 O O p~NH II 777.0 A
N NH

H O
N~N NH
O O O
1 d4 0 0 o~NH 753.0 A
N NH
H O
N~N NH
O O O
105 o o o~NH 737.0 A
N NH
H O
N~N NH2 O O O
106 0 0 o~NH 685.9 A
w ~ NH

H O
N~N NH
O ~'OI O
107 0 o O~NH ~ I 777.0 A
N NH
I
O
H NHZ
'~N
\N' ~ O
O O ,,~ O
108 \ ~-~~. N NH O 747.9 A
N N
O
H O
N~N NH2 109 O O p~NH 698.9 A
N NH
H
H O
N NH
O O N " O
O
110 ~ N NH O 754.0 A
O

H O
N~N NH

111 O o o~NH F 821.0 A
F F
N NH
H O
N~N NHS
0o O
112 0 0 o~NH 684.9 A
N NH
H
O
NH
O O O O
113 ~~ N NH O 766.0 A

O
'N ' N NH
ii O O
O
114 O O O~NH 779.0 A
N NH
H O
N~N NHZ
O O O
115 O O o~NH 699.9 A
NH
N N
H O
N~N NH

116 0 o O~NH 739.0 A
N NH

y/
H O
N~N NH
O O O
117 0 o o~NH 767.0 A
N NH
H O
N~N NHZ
O ~O'I O
118 0 0 oyNH 668.8 A
N INH
H
H O
N~N NHS
O O O
119 O O O"NH 698.9 A
N ~N'H

H O
N~N NH2 120 O O O "NH 682.9 A
N ~NH
I
H O
N~N NH

121 O O O NH 723.9 A
N
H O
N~N NH
O ~O'I O
122 O O O~NH II 720.9 A
N NH
( H O
N~N NH
O O
O
123 0 0 oyNH F 821.0 A
F F
N NH
H O
N~N NHZ
O O
O
124 O O O~NH 682.9 A
N NH
H
H O
N~N NH

125 O O O' .NH 710.9 A
N ~NH

H O
N~N NHS
O O
O
126 0 0 o NH 671.8 A
w H
H O
N~N NH
O O O
127 0 0 o~NH ~ I 709.9 A
NH
N N
H
H O H
N~N N

128 o p o~NH 767.0 A
N NH

H O
N~N NH
O rOI O
129 o O O~NH 684.9 A
N NH
H O
N~N NHZ
O ~O'I O
130 O O O~NH 684.9 A
N NH
H O
N~N NHS
O ~O'I O
131 O O O~NH 656.8 A
N NH

H O
N~N NHZ
O O O
132 0 0 o~NH 670.9 A
N NH
H O
N NH
O O N~ O
133 ~~ N NH O 776.0 A
-i i o II
H O
N~N NH
O O O
134 0 0 o~NH 696.9 A
N NH
H

H O
N~N NH
O O
O
135 0 0 oyNH 728.0 A
v~ INH
N N
H O
N~N NH
O O O
136 O O O-"NH 724.9 A
N ~N'H
H O
N~N NH
o O O
137 O o o~NH 712.9 A
N NH
H

H O
~N NHZ
O O O O O
138 ' ~~ N NH 762.0 A
N N
H O H
N~N N
O O O
139 0 0 o~NH 699.9 A
NH
H
I
H O
N~N NH
O COI O
140 0 0 o~NH 727.0 A
N NH
I

N NHZ
O O O O
141 N NH O 724.9 A
~N
O
H O
N~N NH
O ~O'I O
142 O o p~NH 751.0 A
N NH
H O
N~N NH
O COI O
143 0 0 o~NH 712.9 A
N NH

H O
N~N NH
O O
144 0 0 o NH o 698.9 A
N NH
H O
N~N NHZ
O O O
145 O O O ' -NH 739.0 A
N ~NH
H O
N~N NH

146 O O oyNH 710.9 A
N INH

H O
~N NH
N
O O
O
147 0 o p~NH 713.9 A
NH
N N
H O H
N~N N
O O O
148 O p O~NH 713.9 A
NH
O
H NHz N
O O N O O
149 O 696.9 B
N~NH
IIH
O
O
H O
N~N NH
O O
150 p O p NH o 770.0 B
w N N

The present invention relates to novel HCV protease inhibitors. This utility can be manifested in their ability to inhibit the HCV NS2/NS4a serine protease. A general procedure for such demonstration is illustrated by the following in vitro assay.
Assay for HCV Protease Inhibitory Activity:
Spectrophotometric Assay: Spectrophotometric assay for the HCV serine protease can be performed on the inventive compounds by following the procedure described by R. Zhang et al, Analytical Biochemistry, 270 (1999) 268-275, the disclosure of which is incorporated herein by reference. The assay based on the proteolysis of chromogenic ester substrates is suitable for the continuous monitoring of HCV NS3 protease activity. The substrates are derived from the P side of the NSSA-NSSB junction sequence (Ac-DTEDVVX(Nva), where X = A or P) whose C-terminal carboxyl groups are esterified with one of four different chromophoric alcohols (3- or 4-nitrophenol, 7-hydroxy-4-methyl-coumarin, or 4-phenylazophenol). Illustrated below are the synthesis, characterization and application of these novel spectrophotometric ester substrates to high throughput screening and detailed kinetic evaluation of HCV NS3 protease inhibitors.
Materials and Methods:
Materials: Chemical reagents for assay related buffers are obtained from Sigma Chemical Company (St. Louis, Missouri). Reagents for peptide synthesis were from Aldrich Chemicals, Novabiochem (San Diego, California), Applied Biosystems (Foster City, California) and Perseptive Biosystems (Framingham, Massachusetts). Peptides are synthesized manually or on an automated ABI model 431A synthesizer (from Applied Biosystems). UV/VIS
Spectrometer model LAMBDA 12 was from Perkin Elmer (Norwalk, Connecticut) and 96-well UV plates were obtained from Corning (Corning, New York). The prewarming block can be from USA Scientific (Ocala, Florida) and the 96-well plate vortexer is from Labline Instruments (Melrose Park, Illinois). A Spectramax Plus microtiter plate reader with monochrometer is obtained from Molecular Devices (Sunnyvale, California).
Enzyme Preparation: Recombinant heterodimeric HCV NS3/NS4A protease (strain 1 a) is prepared by using the procedures published previously (D. L.

Sali et al, Biochemistry, 37 (1998) 3392-3401 ). Protein concentrations are determined by the Biorad dye method using recombinant HCV protease standards previously quantified by amino acid analysis. Prior to assay initiation, the enzyme storage buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside and 10 mM DTT) is exchanged for the assay buffer (25 mM MOPS pH 6.5, 300 mM NaCI, 10%
glycerol, 0.05% lauryl maltoside, 5 pM EDTA and 5 pM DTT) utilizing a Biorad Bio-Spin P-6 prepacked column.
Substrate Synthesis and Purification: The synthesis of the substrates is done as reported by R. Zhang et al, (ibid.) and is initiated by anchoring Fmoc-Nva-OH to 2-chlorotrityl chloride resin using a standard protocol (K. Barlos et al, Int. J. Pept. Protein Res., 37 (1991 ), 513-520). The peptides are subsequently assembled, using Fmoc chemistry, either manually or on an automatic ABI
model 431 peptide synthesizer. The N-acetylated and fully protected peptide fragments are cleaved from the resin either by 10% acetic acid (HOAc) and 10% trifluoroethanol (TFE) in dichloromethane (DCM) for 30 min, or by 2%
trifluoroacetic acid (TFA) in DCM for 10 min. The combined filtrate and DCM
wash is evaporated azeotropically (or repeatedly extracted by aqueous Na2C03 solution) to remove the acid used in cleavage. The DCM phase is dried over Na2S04 and evaporated.
The ester substrates are assembled using standard acid-alcohol coupling procedures (K. Holmber et al, Acta Chem. Scand., B33 (1979) 410-412). Peptide fragments are dissolved in anhydrous pyridine (30-60 mg/ml) to which 10 molar equivalents of chromophore and a catalytic amount (0.1 eq.) of para-toluenesulfonic acid (pTSA) were added. Dicyclohexylcarbodiimide (DCC, 3 eq.) is added to initiate the coupling reactions. Product formation is monitored by HPLC and can be found to be complete following 12-72 hour reaction at room temperature. Pyridine solvent is evaporated under vacuum and further removed by azeotropic evaporation with toluene. The peptide ester is deprotected with 95% TFA in DCM for two hours and extracted three times with anhydrous ethyl ether to remove excess chromophore. The deprotected substrate is purified by reversed phase HPLC on a C3 or C8 column with a 30% to 60% acetonitrile gradient (using six column volumes).

The overall yield following HPLC purification can be approximately 20-30%.
The molecular mass can be confirmed by electrospray ionization mass spectroscopy. The substrates are stored in dry powder form under desiccation.
Spectra of Substrates and Products: Spectra of substrates and the corresponding chromophore products are obtained in the pH 6.5 assay buffer.
Extinction coefficients are determined at the optimal off-peak wavelength in 1-cm cuvettes (340 nm for 3-Np and HMC, 370 nm for PAP and 400 nm for 4-Np) using multiple dilutions. The optimal off-peak wavelength is defined as that wavelength yielding the maximum fractional difference in absorbance between substrate and product (product OD - substrate OD)/substrate OD).
Protease Assay: HCV protease assays are performed at 30°C using a 200 p1 reaction mix in a 96-well microtiter plate. Assay buffer conditions (25 mM
MOPS pH 6.5, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside, 5 pM
EDTA and 5 pM DTT) are optimized for the NS3/NS4A heterodimer (D. L. Sali et al, ibid.)). Typically, 150 p1 mixtures of buffer, substrate and inhibitor are placed in wells (final concentration of DMSO <_4 % v/v) and allowed to preincubate at 30 °C for approximately 3 minutes. Fifty pls of prewarmed protease (12 nM, 30°C) in assay buffer, is then used to initiate the reaction (final volume 200 pl).The plates are monitored over the length of the assay (60 minutes) for change in absorbance at the appropriate wavelength (340 nm for 3-Np and HMC, 370 nm for PAP, and 400 nm for 4-Np) using a Spectromax Plus microtiter plate reader equipped with a monochrometer (acceptable results can be obtained with plate readers that utilize cutoff filters). Proteolytic cleavage of the ester linkage between the Nva and the chromophore is monitored at the appropriate wavelength against a no enzyme blank as a control for non-enzymatic hydrolysis. The evaluation of substrate kinetic parameters is performed over a 30-fold substrate concentration range (~6-200 pM). Initial velocities are determined using linear regression and kinetic constants are obtained by fitting the data to the Michaelis-Menten equation using non-linear regression analysis (Mac Curve Fit 1.1, K. Raner).
Turnover numbers (kcat) are calculated assuming the enzyme is fully active.

Evaluation of Inhibitors and Inactivators: The inhibition constants (Ki) for the competitive inhibitors Ac-D-(D-Gla)-L-I-(Cha)-C-OH (27), Ac-DTEDVVA(Nva)-OH and Ac-DTEDVVP(Nva)-OH are determined experimentally at fixed concentrations of enzyme and substrate by plotting vo/vi vs. inhibitor concentration ([I] o) according to the rearranged Michaelis-Menten equation for competitive inhibition kinetics: volvi = 1 + [I] o /(Ki (1 + [S] o /Km)), where vo is the uninhibited initial velocity, vi is the initial velocity in the presence of inhibitor at any given inhibitor concentration ([I]o) and [S]o is the substrate concentration used. The resulting data are fitted using linear regression and the resulting slope, 1/(Ki(1+[S] o/Km), is used to calculate the Ki value. The obtained Ki* values (in nanoMolar)for some of the inventive compounds are shown below in Table 3.
Table 3 structure Ki*
(nM) H~C~CH3 Hz 1.9 ~N N

0 0 p~N
N ICH
N~
CH~
HaC/ \c,.' 3H3 H~C~CH~ H2 .
~N N

HOC ICH
C

"'°~ ", 2.6 ~ N N
Ir l'~ CHINI' ~0 O 0 O O _p~~N
H3p~ ~~_--~ N CIH
H~C~N~
CH3 HOC ~CH
HaC~ NCH a H3C~CH~ ,QHt ~0 ~N N

0 0 O~N CHj H~C'~~~~
CH3 CH~CH
H~C/1C'H~ ' H3C~CH3 ~H=
~N I/N

N~ y'~N
CH~
HaC/ 'C'HoHa "3C~CH~ H= 3 //~~ N N
~~- ,~/CH=NI
~O 0 O
0~~j~ 0 ''O''~~~'' ~-N
~ N ICIH
H,C / 'N//~~
H3C'~~~
C"~ CHH3~CH=
~p~ H3 4 N
~/CH3 NI
~O 0 0 0 O ''0"N
~--~ DIY F F
~_~ F
H3C~ ~--~ N
H3CX 'N~
ICH3 H,C ~C
"3C' ~C"' ~
"_°.~°"_ ~= 4.8 N N
~/CH='N

O 0 ''O''~~~'' ~-N
N
~C N '\
CH= HOC
CHI

"~°~°H~ ~H~ 5.4 p N N
~/CH, NI
~0 0 0 0~\~~jj~v 0 ''O''~~~N'' ~- CH, H,C' ~, [ N
~C~N~
CH, H,C ~CH
H,C~ NCH, ' H3CVCH, Hx N N
~/CH, N' 0 0 ''O''~~~N'' ~- F
~~~![~ F F
H,C~ ~--~ N
H~C~N~
ICH, H,C ~C~
H~C~ ~C~
HaC~ H~ H
N N
~'CH,NI.

0 O _p~TN ~ CH, H,C, ~ N
HaC%~N~
CH, H,C ~pH
H,C~ NCH

H,C~pH, ~NZ 12 ~N rN
0 0 p~N pH, H,CL~~N~ N
CH~pH
H3p/\p'H3 3 While the present invention has been described with in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims (36)

1. A compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers and racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound having the general structure shown in Formula I:
wherein:
R1 is H, OR8, NR9R10, or CHR9R10, wherein R8, R9 and R~° can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, heterocyclyl-, arylalkyl-, and heteroarylalkyl;
A and M can be the same or different, each being independently selected from R, OR, NHR, NRR', SR, SO2R, and halo; or A and M are connected to each other such that the moiety:
shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl;
E is C(H) or C(R);
L is C(H), C(R), CH2C(R), or C(R)CH2;
R, R', R2, and R3 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cycloalkyl)alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-;
or alternately R and R' in NRR' are connected to each other such that NRR' forms a four to eight-membered heterocyclyl;
Y is selected from the following moieties:
wherein Y30 is selected from where u is a number 0-1;
X is selected from O, NR15, NC(O)R16, S, S(O) and SO2;
G is NH or O; and R15, R16, R17, R18, R19, T1, T2, and T3 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or alternately, R17 and R18 are connected to each other to form a three to eight-membered cycloalkyl or heterocyclyl;
wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkyl, aryl, heteroaryl, alkylsulfonamido, arylsulfonamido, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano, and nitro.

2. The compound of claim 1, wherein R1 is NR9R10, and R9 is H, R10 is H, or R14 wherein R14 is H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl, alkenyl, alkynyl or heteroaryl-alkyl.

3. The compound of claim 2, wherein R14 is selected from the group consisting of:

4. The compound of claim 1, wherein R2 is selected from the group consisting of the following moieties:

5. The compound of claim 1, wherein R3 is selected from the group consisting of:
wherein R31 is OH or O-alkyl; and R32 is H, C(O)CH3, C(O)OtBu or C(O)N(H)tBu.

6. The compound of claim 5, wherein R3 is selected from the group consisting of the following moieties:

7. The compound of claim 1, wherein G is NH.

8. The compound of claim 7, wherein Y is selected from the following moieties:

wherein Y32 is selected from the group consisting of:
Y30 is selected from where a is a number 0-1;

and R19 is selected from H, alkyl, phenyl or benzyl.

9. The compound of claim 8, wherein T1 and T2 can be the same or different, each being independently selected from the group consisting of:
or the moiety:
taken together represents and T3 is selected from:

10. The compound of claim 1, wherein the moiety:
is selected from the following structures:

11. The compound of claim 10, wherein the moiety:

is selected from the following structures:

12. The compound of claim 11, wherein the moiety:
is selected from the following structures:

13. The compound of claim 1, wherein R1 is NHR14, where R14 is selected from the group consisting of:
R2 is selected from the group consisting of the following moieties:
R3 is selected from the group consisting of the following moieties:
Y30 is selected from the group consisting of:
and also wherein Y30 is selected from the group consisting of:
and also wherein Y30 is selected from the group consisting of:
Y32 is selected from the group consisting of:

and Y12 is selected from the group consisting of H, CO2H, CO2Me, OMe, F, Cl, Br, NH2, N(H)S(O2)CH3, N(H)C(O)CH3, NO2, NMe2, S(O2)NH2, CF3, Me, OH, OCF3, and C(O)NH2 and Y33 is selected from the group consisting of:
and T3 selected from:
and the moiety:

14. A pharmaceutical composition comprising as an active ingredient at least one compound of claim 1.

15. The pharmaceutical composition of claim 14 for use in treating disorders associated with HCV.

16. The pharmaceutical composition of claim 15 additionally comprising at least one pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 16, additionally containing at least one antiviral agent.

18. The pharmaceutical composition of claim 17, still additionally containing at least one interferon.

19. The pharmaceutical composition of claim 18, wherein said at least one antiviral agent is ribavirin and said at least one interferon is .alpha.-interferon or pegylated interferon.

20. A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of at least one compound of claim 1.

21. The method of claim 20, wherein said administration is oral or subcutaneous.

22. The use of a compound of claim 1 for the manufacture of a medicament to treat disorders associated with the HCV.

23. A method of preparing a pharmaceutical composition for treating the disorders associated with the HCV, said method comprising bringing into intimate physical contact at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

24. A compound exhibiting HCV protease inhibitory activity, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers and racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound being selected from the compounds of structures listed below:

25. A pharmaceutical composition for treating disorders associated with the HCV, said composition comprising therapeutically effective amount of one or more compounds in claim 24 and a pharmaceutically acceptable carrier.

26. The pharmaceutical composition of claim 25, additionally containing at least one antiviral agent.

27. The pharmaceutical composition of claim 26, additionally containing at least one interferon or PEG-interferon alpha conjugate.

28. The pharmaceutical composition of claim 27, wherein said at least one antiviral agent is ribavirin and said at least one interferon is .alpha.-interferon or pegylated interferon.

29. A method of treatment of a hepatitis C virus ("HCV") associated disorder, comprising administering an effective amount of one or more compounds of claim 24.

30. A method of modulating the activity of hepatitis C virus protease, comprising contacting HCV protease with one or more compounds of claim 24.

31. A method of treating, preventing, or ameliorating one or more symptoms of hepatitis C, comprising administering a therapeutically effective amount of one or more compounds of claim 24.

32. The method of claim 31, wherein the HCV protease is the NS3/NS4a protease.

33. The method of claim 32, wherein the compound or compounds inhibit HCV NS3/NS4a protease.

34. A method of modulating the processing of hepatitis C virus (HCV) polypeptide, comprising contacting a composition containing the HCV
polypeptide under conditions in which said polypeptide is processed with one or more compounds of claim 24.

35. A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment, a pharmaceutical composition which comprises therapeutically effective amounts of at least one compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers and racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound being selected from the following:

36. A compound of claim 1 in purified form.